The impact of HLA-DM on peptide binding to MHC class II by Templeton, Megan
THE IMPACT OF HLA-DM ON PEPTIDE BINDING TO MHC CLASS II
RECOMMENDED:
APPROVED:
By
Megan Templeton
Dr. Karsten Hueffer 
Advisory Committee Member
Dr. Thomas Kuhn 
Advisory Committee Co-chair
Advisory Committee Co-chair
OTi
Dr. Thomas Green
Chair, Department of Chemistry and Biochemistry
Dr. Paul Layer 
Dean, College of Natural ence and Mathematics
Jr. John Eichelberger 
Dean of the Graduate School -

THE IMPACT OF HLA-DM ON PEPTIDE BINDING TO MHC CLASS II
A
THESIS
Presented to the Faculty 
of the University of Alaska Fairbanks
in Partial Fulfillment of the Requirements 
for the Degree of
MASTER OF SCIENCE
By
Megan Templeton, B.S. 
Fairbanks, AK
May 2016
Abstract
Recognition of peptides bound to class II major histocompatibility complex (MHCII) 
molecules by T cell receptors of CD4+ T cells initiates an adaptive immune response. Analysis 
of the antigen presentation pathway indicates that elements of the epitope selection process are 
critical to generation of the peptide repertoire presented to T cells. Antigen presentation by 
dedicated cells (APCs) involves the intracellular fragmentation of protein antigens by cathepsins, 
binding of the derived peptide epitopes to MHCII with the participation of the peptide-editing 
molecule HLA-DM (DM), and subsequent transport to the surface for recognition. This thesis 
focuses on the energetics and structural flexibility of the peptide-MHCII complex, and their 
correlation with DM-susceptibility, to identify the criteria associated with the selection of 
peptides by APCs for subsequent presentation to T cells.
Using the human MHCII HLA-DR (DR), and peptides derived from influenza H3 
HA305-3i8 as test system, it was observed that, in the absence of DM, stable peptide binding is not 
reached through independent contributions of single-point interactions, but is a distributive 
process that involves the peptide-DR groove dyad in its entirety highlighting the inherent 
flexibility of the binding process. Here, DM mechanism is investigated in its ability to impact 
structural flexibility of the complex. Analysis of release from and binding to DR of a gamut of 
HA-derived peptides at two different levels of pH reveals that structural stability is reduced as a 
consequence of DM function. The results indicate that the outcome of DM activity is favoring 
the endurance of complexes with limited structural flexibility.
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Chapter 1 An Introduction to Antigen Binding to MHC Molecules
1.1 Introduction to Major Histocompatibility Complex (MHC)
An essential part of the immune system is to differentiate between self and non-self, a task 
that relies on the activity of white blood cells known as lymphocytes. The adaptive immune 
system, in particular, has evolved the capacity to recognize and respond to each pathogen in a 
specific fashion; such capacity differentiates the adaptive from the innate immune system, which 
features a quicker but more generic response. One subset of lymphocytes, B cells, is responsible 
for the generation of antibodies, which form the humoral branch of the adaptive response. A 
second subset of lymphocytes known as T cells constitutes the pillar of the cell-mediated 
immune response. These cells are characterized by their membrane receptor, known as T cell 
receptor (TCR). TCRs cannot directly bind pathogens; instead they can only interact with 
pathogen-derived peptides (antigens) when presented with molecules of the major 
histocompatibility complex (MHC) on other cells’ membrane.
MHC binds peptides, the origin of which can be extremely variable, from self-proteins to viral 
components. MHC molecules are divided in three classes, with class I and II molecules being 
responsible for peptide presentation to T cells (1). T helper cells, or CD4+ T cells, recognize 
MHC class II molecules (MHCII) that are found on the surface of professional antigen 
presenting cells (APC). Variations of APC include: B cells, dendritic cells, macrophages, and 
epithelial cells of the thymus. Once CD4+ T cells are activated by APC, they proliferate, 
differentiate and they secrete small signaling proteins called cytokines that aid other immune 
cells. The cytotoxic T cells, or CD8+ T cells, recognize MHC class I molecules (MHCI), 
expressed on the surface of all nucleated cells. Once activated, CD8+ T cells will release 
granules containing perforin and granzymes that can destroy the targeted cell. MHCI bind and 
present peptides derived from intracellular proteins, while MHCII present peptides derived from 
extracellular proteins (2). The process of antigen presentation is an essential aspect to the 
generation of a specific T cell response, which is required to recognize and respond to infected or 
abnormal cells.
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1.2 MHC Genetics
The importance of the MHC system became apparent in the context of organ transplantation, 
as it was clear that the basis of acceptance or rejection of a tissue is constituted by the matching 
between donor and recipient MHC alleles. Population analysis of MHC alleles has indicated that 
they are the most polymorphic proteins encoded by the human genome (3). The human MHC is 
named human leukocyte antigen (HLA), is encoded on chromosome 6 and the MHC locus 
contains 3.6 megabase pairs. The HLA system encompasses closely linked genes, which are 
inherited and is often associated with autoimmune diseases, like rheumatoid arthritis and 
diabetes (4). For each one of the two main HLA classes, three functional loci have been 
identified: the HLA class I includes, HLA-A, HLA-B and HLA-C loci, whereas the HLA class II 
includes, HLA-DR, HLA-DQ and HLA-DP. The allele we utilize in our experiments is HLA- 
DR1 (DR1). Although the evolution of the MHC system and its large polymorphism have led to 
an increased protection from infectious diseases, it is also likely that they are associated with an 
increased prevalence in autoimmune diseases (5).
1.3 Antigen Presentation Pathways
Antigen processing and presentation are the sequence of events that lead to the generation of 
peptides/MHC complexes for recognition by T cells. The antigenic peptides can derive from 
tumoral proteins, protein of intracellular pathogens or simply self-proteins targeted for removal. 
These peptides are usually presented by MHCI as a result of the endogenous pathway. If the 
peptides are generated from engulfed antigens, they are presented by MHCII at the end of the 
exogenous pathway.
In the endogenous pathway, the peptides originate from degraded or misfolded proteins from 
within the cell, which are ubiquitinated, marking them for proteasome degradation. The 
proteasome is a large, barrel-like protein complex with proteolytic activity, and peptidases (6). 
Polypeptides generated by the proteasome in the cytosol are transported into the endoplasmic 
reticulum (ER) through an ATP-dependent mechanism involving the transporter associated with 
antigen processing (TAP). MHCI molecules are synthesized within the ER and resident 
chaperones facilitate its appropriate folding. The MHC class I (heavy chain and p2- 
microglobulin) binds to the intraluminal face of TAP in a complex with the chaperones 
calreticulum and ERp57. Critical to this interaction is tapasin, which acts as a bridging molecule 
between the MHCI bound to the chaperone complex and TAP. Tapasin does not simply link
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nascent MHCI molecules to TAP, but it is also required to facilitate binding of high affinity 
peptides to the MHCI. After peptide loading, MHCI dissociates from TAP and cluster at export 
sites on the ER membrane where they are selectively recruited into cargo vesicles for transport to 
the Golgi apparatus (7). MHCI then traffics through the Golgi apparatus to the plasma 
membrane.
The exogenous antigen processing begins within the ER of APCs, where the MHCII is 
synthesized as a heterodimer composed of aP subunits, which are then complexed with a trimer 
formed by three copies of the protein invariant chain (Ii). Binding to Ii prevents inappropriate 
endogenous peptides from infiltrating the binding groove, and provides the aP heterodimers with 
Ii sorting motifs for correct trafficking to the antigen processing compartments (8). The MHCII 
bound to Ii is transported directly or through an intermediate stop at the plasma membrane, to a 
specialized vesicle that is termed MHC class II compartment (MIIC) (9). When the Ii-MHCII 
complex reaches the acidic MIIC, the Ii is cleaved in a stepwise fashion by the proteolytic action 
of cathepsins (in particular cathepsin S and L), leaving a smaller peptide fragment named class 
II-associated invariant chain-derived peptide (CLIP) in the binding groove. A “non-classical” 
class II molecule, HLA-DM (DM) acts as an enzyme, promoting CLIP removal from the binding 
groove and antigenic peptide binding to MHCII. The entire process is shown in Figure 1.1, and 
represents the molecular machinery that entails the uptake of the pathogen by the APC, 
transportation within early and late endosomes through the cytoplasm, fusion within lysosomal 
vesicles and degradation via proteases. As classical and non-classical MHCII molecules populate 
these compartments, the MIIC is formed. Although MHCII loading can occur at any of these 
stages, the MIIC, with its acidic pH (~5.0 -  5.5), DM, and proteases, constitutes the ideal 
environment for peptide binding and DM activity. As kinetically and energetically stable 
peptide/MHCII complexes are formed, then they are transferred to the plasma membrane for 
subsequent recognition by CD4+ T cells.
1.4 Structure of MHC
MHCI molecules are composed of a single a chain, in which 3 domains can be identified (a1 
a2 and a3) covalently associated to the polypeptide p2-microglobulin. The a1 and a2 domains 
are membrane-distal and form the site where peptides bind, which is also called the peptide 
binding groove. The MHCI binding groove is closed off, thus only peptides of 8 to 9 amino acids 
in length can be accommodated without kinks or bulges.
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MHCII molecules are heterodimer proteins composed of two chains, a and P, in which four 
domains a1a2p1p2 can be identified. The a1 and P1 domains are membrane-distal regions 
forming the peptide binding site, whereas the membrane-proximal a2 and P2 feature the typical 
Ig-like fold and are responsible for the anchoring to the membrane (APC cell surface or 
intracellular vesicle). The HLA class II peptide binding groove features a floor of eight strands of 
P sheet surrounded by two a-helices (10). Differently from MHCI, the MHCII has an open 
binding groove that can bind 12 to 17 amino acid residues. As peptides interact with the MHCII, 
they take a polyproline type II-like helix conformation, with side chains that interact with the 
binding groove of DR1 and 13 or more hydrogen bonds (H-bonds) established between the 
peptide backbone and the surrounding a-helices (11). Lining the floor of the binding groove is a 
group of pockets, referred to as P1, P4, P6 (sometimes P7) and P9, which are able to encapsulate 
peptide side chains. Various models have been put forth that account for the impact of the 
different pockets and H-bonds on peptide binding in the attempt to predict which sequences will 
be more likely to create an immune response.
1.5 Peptide Binding to MHC
Initial models describing peptide binding to MHC adopted the lock and key view, which has 
been historically used to describe ligand-receptor and enzyme-substrate interactions. More 
recently, the peptide binding process has been considered as a flexible event, during which the 
peptide folds itself and the binding groove to a low energy conformation. There are two 
approaches to model how peptide binds MHCII. The first model focuses on the role of the P1 
anchor-pocket interaction in generating a stable complex. The P1 pocket is the largest and most 
hydrophobic pocket of the binding groove (in many, but not all alleles). This model originated 
from SDS gel studies where peptides able to fill the P1 pocket would preserve the MHCII 
dimeric conformation, whereas unbound or low affinity peptides would favor MHCII 
dissociation in two chains (12). These observations led to the idea that peptides with a lower 
affinity for MHCII are responsible for generating an empty or flexible P1 pocket that are more 
susceptible to DM action (13).
This model is opposed by a second model that indicates the overall dynamics of the peptide 
binding to MHCII as the primary target of DM recognition. Indeed, the second model postulates 
that DM susceptibility is based on the interactions and conformational changes that occur 
throughout the whole binding site as consequence peptide binding. A previous study showed that
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multiple peptide substitutions at positions that do not interact with MHCII pockets affected 
binding affinity more than a single substitution at the P1 pocket; thus, when analyzing peptide 
binding, it is important to take into account the entire peptide (14). Subsequent studies found a 
way to measure the conformational flexibility of the MHCII binding peptide through 
cooperativity (15). The mechanism of peptide binding to MHCII and the role of DM in the 
selection of epitopes are yet to be determined.
1.6 Role of Non-classical MHCII Molecules
The polymorphism of DM was identified in cells with a defect in the process of peptide 
binding to MHCII (16). Subsequent analysis led to the realization that DM increased peptide 
dissociation from MHCII as well as increasing the peptide association with MHCII (17). 
However it became rapidly evident that DM does not act like a typical catalyst, in that it is 
unable to bind peptide, despite the MHCII-like structure. Instead, DM only interacts with 
MHCII.
In order to generate a T cell response, a peptide complexed to MHCII must be kinetically 
stable. DM enhances the binding of peptides that bind stably to MHCII, and it decreases the 
binding of unstable peptides (18). The measurement to determine DM susceptibility has 
frequently been that of peptide dissociation from MHCII in the presence of DM. Previous 
experiments have shown that peptides that quickly dissociate from MHCII were susceptible to 
DM, whereas the more stable peptide were less susceptible to DM (17). Recently it has been 
discovered that peptides that stay bound to MHCII for more than 75 hours will generate a 
specific T cell response, those that stay bound less than 10 hours will be unable to create a 
comparable response (19). Clearly, DM plays a large role in the endosomal selection of 
peptide/MHCII complexes destined to T cell recognition; DM with MHCII interaction can be 
better understood through the structural interpretation.
Initial studies indicated that DM is able to mediate CLIP removal from MHCII. Later work 
showed that DM activity is not limited to CLIP, in that it is able to catalyze exchange of 
antigenic peptides to select for a repertoire of kinetically and energetically stable peptide/MHCII 
complexes (20). The mechanism by which DM interacts with MHCII and alters peptide binding 
and release has not been fully elucidated yet. For many years it was impossible to determine a 
crystal structure of MHCII interacting with DM; in the last four years studies have overcome the 
previous quandary through various methods. Pos and colleagues (21) were able to capture the
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structure of DM interacting with DR1 bound to a partial HA peptide missing the P-1, P1, and P2 
positions (leaving the P1 pocket empty) and linked by a disulfide bound at the P6 pocket. 
Visualizing the structure was accomplished by linking DR1 with DM by their P subunits with 
sortase A (21). The resolved crystal structure is shown in Figure 1.2. This structure provided 
confirmation to prior studies adopting indirect approaches, which suggested that DM interacts 
with DR1 at the N-terminal by targeting the a-helix.
Another non-classical MHC molecule that is involved in the exogenous pathway of antigen 
presentation is HLA-DO (DO). Although still debated, it appears that the role of DO would be 
that of inhibiting DM, by competing with MHCII for binding to the same location on DM (22). 
Structurally, DO is similar to MHCII, and it would interact with DM via the same molecular 
region involved in the binding of MHCII to DM. The amount of DO is regulated by 
transcription, and it appears that there is a higher concentration of DM within the MIIC, 
therefore DM would be partially involved in DM-DO complexes and the remaining DM would 
be amenable to interact with classical MHCII (23).
1.7 The Importance of Peptide Binding
Explaining peptide binding to MHC and the subsequent presentation to T cells has a wide 
variety of implications, from understanding the immune response to a typical pathogen infection 
to being able to determine better options for peptide-based vaccinations. The clinical importance 
of antigen presentation can be seen when self peptides bind MHCII, potentially leading to 
autoimmune disorders in the context of reduced tolerance: for instance certain defects in HLA- 
DQ alleles can lead to celiac disease and type 1 diabetes (24). During cancer, tumoral cells have 
been shown to hijack antigen presentation to avoid detection from T cells, and some malignant 
tumors down regulate MHC expression with the same purpose (25).
Considering the breadth of the potential antigenic repertoire, and the polymorphism of HLA 
molecules, being able to predict if certain peptides will bind specific alleles would allow 
development of peptide-based vaccines, identification of self-epitopes correlated with 
autoimmunity, and could be adopted for epidemiological purposes. It would be nearly 
impossible, costly and time-consuming, to experimentally measure binding of all possible amino 
acid combinations for all known alleles. To overcome the limitations of in vitro measurement, in 
silico peptide binding prediction algorithms have been engineered. There are two approaches to 
predict peptides, a direct method, which predicts epitopes based on what the T cell receptor will
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recognize (these have been less successful), or an indirect method, based on which epitope will 
bind the MHC (26). Reliable peptide binding prediction algorithms would greatly benefit vaccine 
development, from the seasonal influenza to the Ebola virus (27, 28). However, the precision of 
the current prediction models is questionable, in particular for MHCII binding: one study showed 
that T cell response to predicted Pseudomonas exotoxin five epitopes were correctly predicted, 
however another four were missed entirely (29). An explanation for some of the missing epitopes 
might be that algorithms do not take into account DM action in the process of prediction or the 
role of MHCII structural flexibility during peptide binding. A better understanding of DM 
activity during antigen presentation, and its inclusion in prediction algorithms would 
dramatically increase our ability to engineer reliable T cell epitopes mapping models.
1.8 Hypothesis
The purpose of our experiments is to investigate DM function and the impact it has on the 
structural flexibility of the peptide/MHCII complex. Previous studies have shown that measuring 
cooperativity of interactions within the binding groove is a suitable approach to better probe the 
peptide binding process (30). On the basis of our prior analysis of cooperativity in peptide 
binding to and release from MHCII in the absence of DM, and the structural and kinetic studies 
of DM activity reported above, we predict that DM will favor the survival of peptide/MHCII 
complexes in which structural flexibility is limited. We will test our hypothesis by quantitating 
cooperative effects on binding to and release from the human MHCII HLA-DR1 as determined 
with cycle-mutated peptides derived from the sequence of the influenza peptide HA305-318 (31, 
32).
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1.9 Figures
Figure 1.1 Exogenous Pathway of Antigen Presentation
Within antigen presenting cells, exogenous proteins are cleaved and the resulting peptides are 
loaded onto the MHCII, transported to the surface of the cell, and presented to CD4+ T cells.
8
Figure 1.2 Crystal Structure of DM and DR (PDB: 4GBX)
DMa chain is shown in magenta, the DMP chain in yellow, the DRa chain in green, and DRP 
subunit in blue. An HA peptide lacking three N-terminal residues is shown in pink. The structure 
of PDB: 4GBX was modeled in PyMol, coordinates are taken from Pos, et al (21).
9
1.10 References
1. Paul WE. Fundamental Immunology: Wolters Kluwer Health; 2012.
2. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol.
2013 Jan; 31(1): 443-73.
3. Beck S, Trowsdale J. The human major histocompatibility complex: lessons from the DNA
sequence. Annu Rev Genomics Hum Genet. 2000; 1(1): 117-37.
4. Consortium. Complete sequence and gene map of a human major histocompatibility complex.
Nature. 1999 Oct; 401(6756): 921-3.
5. Gruen JR, Weissman SM. Evolving views of the major histocompatibility complex. Blood.
1997 Dec; 90(11): 4252-65.
6. Lazaro S, Gamarra D, Del Val M. Proteolytic enzymes involved in MHC class I antigen
processing: a guerrilla army that partners with the proteasome. Molecular Immunology. 
2015 May; 68: 72-76.
7. Raghavan M, Cid ND, Rizvi SM, Peters LR. MHC class I assembly: out and about. Trends
Immunol. 2008 Sep; 29(9): 436-43.
8. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol. 1997 Feb; 9(1):
89-96.
9. Katz JF, Stebbins C, Ettore A, Sant AJ. Invariant chain and DM edit self-peptide presentation
by major histocompatibility complex (MHC) class II molecules. The Journal of 
Experimental Medicine. 1996 Nov; 184(5): 1747-53.
10. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three­
dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 
1993 Jul; 364(6432): 33-9.
11. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal
structure of the human class II MHC protein HLA-DR1 complexed with an influenza 
virus peptide. Nature. 1994 Mar; 368(6468): 215-21.
12. McFarland BJ, Beeson C. Binding interactions between peptides and proteins of the class II
major histocompatibility complex. Med Res Rev. 2002 Mar; 22(2): 168-203.
13. Chou CL, Sadegh-Nasseri S. HLA-DM Recognizes the flexible conformation of major
histocompatibility complex class II. The Journal of Experimental Medicine. 2000 Dec; 
192(12): 1697-706.
10
14. Anderson MW, Gorski J. Cutting edge: TCR contacts as anchors: effects on affinity and
HLA-DM stability. J Immunol. 2003 Dec; 171(11): 5683-7.
15. Anderson MW, Gorski J. Cooperativity during the formation of peptide/MHC class II
complexes. Biochemistry. 2005 Apr; 44(15): 5617-24.
16. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and
presentation of exogenous antigens in mutants with normal HLA class II genes. Nature. 
1990 Jan; 343(6253): 71-4.
17. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, et al. Mediation by
HLA-DM of dissociation of peptides from HLA-DR. Nature. 1995 Jun; 375(6534):802-6.
18. Sant AJ, Chaves FA, Jenks SA, Richards KA, Menges P, Weaver JM, et al. The relationship
between immunodominance, DM editing, and the kinetic stability of MHC class II: 
peptide complexes. Immunol Rev. 2005 Oct; 207(1): 261-78.
19. Sant AJ, Chaves FA, Leddon SA, Tung J. The control of the specificity of CD4 T cell
responses: thresholds, breakpoints, and ceilings. Front Immunology. 2013 Oct; 4: 340.
20. Kropshofer H, Arndt SO, Moldenhauer G, Hammerling GJ, Vogt AB. HLA-DM acts as a
molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity. 
1997 Mar; 6(3): 293-302.
21. Pos W, Sethi DK, Wucherpfennig KW. Mechanisms of peptide repertoire selection by HLA-
DM. Trends in Immunology. 2013 Oct; 34(10): 495-501.
22. Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, Mellins ED, et al. HLA-DO acts as a
substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol. 
2013 Dec; 20(1): 90-8.
23. Denzin LK, Cresswell P. Sibling rivalry: competition between MHC class II family members
inhibits immunity. Nat Struct Mol Biol. 2013 Jan; 20(1): 7-10.
24. Busch R, De Riva A, Hadjinicolaou AV, Jiang W, Hou T, Mellins ED. On the perils of poor
editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with 
celiac disease and type 1 diabetes. Expert Rev Mol Med. 2012 Jul.
25. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor
growth. Immunol Today. 2000 Sep; 21(9): 455-64.
11
26. Goodswen SJ, Kennedy PJ, Ellis JT. Enhancing in silico protein-based vaccine discovery for
eukaryotic pathogens using predicted peptide-MHC binding and peptide conservation 
scores. PloS One. 2014 Dec; 9(12): 1-20.
27. Khan MA, Hossain MU, Rakib-Uz-Zaman SM, Morshed MN. Epitope-based peptide vaccine
design and target site depiction against Ebola viruses: an immunoinformatics study.
Scand J Immunol. 2015 Jul; 82(1): 25-34.
28. Shahsavandi S, Ebrahimi M, Sadeghi K, Mahravani H. Design of a heterosubtypic epitope-
based peptide vaccine fused with hemokinin-1 against influenza viruses. Virol Sin. 2015 
Jun; 30(3): 200-7.
29. Mazor R, Tai CH, Lee B, Pastan I. Poor correlation between T-cell activation assays and
HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas 
exotoxin A. J Immunol Methods. 2015 Oct; 10-20.
30. Ferrante A, Gorski J. Cooperativity of hydrophobic anchor interactions: evidence for epitope
selection by MHC class II as a folding process. J Immunol. 2007 Jul; 178: 7181-89.
31. Horovitz A, Fersht AR. Strategy for analysing the co-operativity of intramolecular
interactions in peptides and proteins. J Mol Biol. 1990 Aug; 214(3): 613-7.
32. Horovitz A, Fersht AR. Co-operative interactions during protein folding. J Mol Biol. 1992
Apr; 224(3): 733-40.
12
Chapter 2 HLA-DM Influences Epitope Selection by Favoring the Survival of Structurally 
Restrained Peptide-MHC Class II Complexes1
2.1 Abstract
HLA-DM (DM) plays a critical role in generating the peptide-MHC class II (MHCII) 
repertoire expressed on the surface of antigen presenting cells and recognized by CD4+ T cells. 
The action of DM requires acidic conditions, and its catalytic effect increases as pH lowers. We 
have previously shown that at pH 7.4 in the absence of DM, peptide binding to and release from 
MHCII is a flexible process as evidenced by cooperativity. Cooperativity indicates that peptide 
binding does not rely on independent contributions of single-point interactions, instead multiple 
interactions along the peptide binding groove determine binding in a non-additive fashion. 
However, it is still unclear whether the system of flexibility represented by cooperativity of 
binding is a function of DM activity. To address this issue, we have measured the cooperative 
effects involved in the interaction between a panel of cycle-mutated peptides derived from the 
sequence of the influenza peptide HA305-318 and the human MHCII allele HLA-DR1 (DR1) in the 
presence of DM. Peptide release studies and competitive binding assays performed at pH 5.4 and 
pH 6.4 show that cooperativity in peptide binding is reduced and this effect is magnified at low 
pH, suggesting that this is a DM-dependent phenomenon. Taken together, our results indicate the 
outcome of DM activity is favoring the survival of complexes with limited structural flexibility.
1 Templeton, M.L., and A. Ferrante. 2015. HLA-DM impacts epitope selection by favoring the 
survival of structurally restrained peptide-MHC class II complexes. Prepared for Cellular & 
Molecular Immunology.
2 Ferrante A., Templeton, M., Hoffman, M., and Castellini, M. The Thermodynamic Mechanism
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2.2 Introduction
During an immunization or infection, exogenous antigens are engulfed and processed by 
antigen presenting cells (APC) within endosomal compartments. Peptides generated via 
proteolytic cleavage by cathepsins are then selected for binding to MHC class II (MHCII) 
molecules, and the resulting complexes are relocated to the cell membrane and presented to 
CD4+ T cells (1). The process of which peptide is selected for binding to MHCII is key to 
consequential recognition by the T cell receptor to initiate a CD4+ T cell response. The MHCII 
is an aP heterodimer synthesized bound to the protein invariant chain (Ii), which prevents 
binding of protein prematurely; the Ii MHCII complex is then transported to a specialized vesicle 
known as MHC class II compartment (MIIC) (2). Once inside the low pH of MIIC, Ii is cleaved 
by proteasomes into a smaller peptide termed class II-associated invariant chain peptide (CLIP) 
that remains within the binding groove of MHCII. For many MHCII alleles HLA-DM (DM), a 
non-classical MHCII molecule, facilitates the removal of CLIP, enabling peptides generated 
from exogenous proteins to compete for binding. It is known that DM promotes the decision by 
the endosomal machinery as to which peptides will be selected and presented by the MHCII. The 
peptide bound to MHCII (pMHCII) repertoire, in the presence of DM, is skewed in favor of 
energetically stable complexes (3). The molecular mechanism behind this process, however, is 
poorly understood.
The interaction between the peptides and MHCII has been extensively studied. The specific 
MHCII allele HLA-DR1 (DR1) is the focus of this study; the binding groove is composed of a P 
sheet, surrounded by two a-helices (4). As with many MHCII proteins, DR1 binds with what are 
referred to as anchor interactions at the P1, P4, P6, and P9 positions within the binding groove, 
where the pockets are deep and hydrophobic (5). In addition to these largely solvent inaccessible 
interactions, positions with smaller pockets or shelves in the binding site accommodating the P2, 
P3, P7, and P10 residues are recognized as minor or auxiliary anchors. Finally, there is a 
conserved array of hydrogen bonds (H-bonds) from side chains in the MHCII to the main chain 
atoms of the peptide.
The crystal structure of DR1 in complex with DM, as wells as mutagenesis studies, have 
shown that DM interacts at the N-terminal of the binding groove in the region adjacent to the P1 
and P2 pocket, possibly a displaced form of the a-helix of DR1 which moves away from the 
binding groove (6). This observation implies that the peptide residue that is occupying the P1
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pocket will have a lasting effect on peptide stability in the presence of DM. The peptide that is 
binding to the MHCII needs to have a high affinity and long half-life in order to stay bound long 
enough on the surface of the APC to be recognized by the CD4+ T cell. There has been an 
indication that DM consistently seems to favor these high affinity (KD) and longer half-life (t1/2) 
peptides to bind the DR1, rather than their unstable peptide counterparts (7). These experiments 
aim to determine the function of DM by means of dissociation and binding kinetics.
Our past analysis performed at physiological pH and in the absence of DM has evidenced that 
pMHCII complex affinity and kinetic stability do not rely on independent contributions from 
single-point interactions (8). Rather, during peptide binding, all sources of binding energy are 
coupled, in that the inability of binding at one position reduces the likelihood of binding at any 
other positions. Therefore the impact of destabilizing one interaction on the overall binding 
process is not constant, but is a function of the total binding energy available to the complex, this 
is termed cooperativity. Subsequently, we analyzed the thermodynamics of the peptide binding 
reaction this can be seen in the paper attached in the appendix (9). The collected observations 
suggest a thermodynamic-structural model where peptides binding DR1 optimize the available 
interactions through search of conformational space, and as they bind, system flexibility is 
restrained.
Here we analyze DM function under the hypothesis that its interaction with the pMHCII 
complex impacts the structural stability of the same complex. We measure cooperative effects 
involved in the interaction between a panel of cycle-mutated peptides derived from the influenza 
peptide HA305-318 and DR1 in the presence of DM at different conditions of pH (10, 11). Taken 
together, our results indicate that DM activity is favoring the survival of complexes with limited 
structural flexibility.
2.3 Methods and Materials 
Peptide Synthesis
Peptides derived from the sequence GPKYVKQNTLKLAT, representing residues 305­
318 of the hemagglutinin (HA) protein from influenza A virus (H3 subtype), are listed in Table
2.1 (4). The N-terminal Gly facilitated labeling. Side chains in the HA peptide are numbered 
relative to the P1Y residue. N-terminal labeling with FAM or LC-LC Biotin was performed on 
the resin before deprotection, and then peptides were cleaved and purified by HPLC and
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confirmed by MALDITOF mass spectrometry. Peptides were provided by AnaSpec Inc.
Fremont, CA.
Expression and purification of recombinant soluble DR1 protein
Recombinant soluble empty (peptide free) DR1 was produced and purified by ioGenetics 
(Madison, WI) from a stably transfected CHO mammalian cell line with a proprietary retroviral 
vector transduction system essentially as described for antibodies. The genes code for proteins of 
192 (a) and 198 (P) residues, which terminate just before the beginning of the predicted 
transmembrane spans (residues 193-197 and 199-203 respectively). The vector was designed to 
generate a poly-His tag at the C-terminus of the expressed protein. DR-expressing clones were 
selected and expanded. His-tagged DR1 proteins were purified with a His-trap HP column 
coupled to an AKTAFPLC chromatography system, and buffer exchanged into PBS (7 mM 
Na+/K+ phosphate, 135 mM NaCl, pH 7.4) using centrifugal ultra-filtration (Amicon). Soluble 
FLAG-tagged DM was isolated from a stably transfected Drosophila S2 cell line as described by 
Arvis Proteins Inc. To avoid contamination with FLAG peptide, DM elution from the resin was 
performed with 0.1 M glycine HCl, pH 3.5. Both DR1 and DM proteins were purified and buffer 
exchanged into K/Na-phosphate buffer (1.47 mM KH2PO4, 8.1 mM Na2HPO4, 135 mM NaCl,
2.7 mM KCl, pH 7.4) using centrifugal ultra-filtration (Amicon). Purity (>95%) was confirmed 
by SDS-PAGE stained with GelCode Blue Stain Reagent (Pierce).
Fluorescence polarization (FP) dissociation measurements
DR/peptide complexes were formed by incubating 1 ^M DR1 with a 10-fold excess of 
FAM-labeled peptide in PBS @ 37°C over night, and purified from unbound peptide by buffer 
exchange into PBS (pH 7.4) @ 4°C with a Centricon YM-30 spin filter (Amicon) previously 
treated with MES. 100 nM of purified DR1/peptide complexes were incubated with 100-fold 
excess of unlabeled HA 305-318 peptide to prevent rebinding of freshly dissociated peptide in 
the presence of 3-fold excess DM. Reactions were performed @ 37°C in 50 mM sodium 
citrate/sodium phosphate buffer at pH 5.4 or MES buffer at pH 6.4 and were covered with 
mineral oil to prevent evaporation. Fluorescence polarization was monitored for 580 and 800 
minutes after addition of the peptide and DM until equilibrium was reached. To avoid non­
specific adherence of the protein, black polystyrene 96-well plates were used (Corning). 
Measurements were performed using a Wallac VICTOR counter (PerkinElmer Wallac) with the
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excitation wavelength=485 nm and emission wavelength=535 nm. Specific control groups 
included (a) protein only, (b) peptide only, and (c) buffer only, and were used for background 
correction. FP and anisotropy are mathematically related ways of expressing 
parallel:perpendicular emission ratios and are easily interconverted. Although FP is 
approximately linear with respect to the ratio of free:bound peptide, FP was converted to 
anisotropy (which is exactly linear) by the following equation A =2*FP/(3-FP) where A is 
anisotropy and FP indicates fluorescence polarization in mP units. Anisotropy values were fitted 
either according to a single- or a bi- exponential decay model to find the t1/2 where 50% of the 
complex was remaining. Each experiment was performed in triplicate, and the reported 
dissociation rate reflects the mean±SD of three independent experiments.
Equilibrium-based competition binding assay
Relative binding affinities were determined by a competitive binding assay essentially as 
described previously (12, 13). DR1 (40 or 80 nm) was incubated with equimolar amount of 
biotinylated HA peptide and three-fold DM in binding buffers (0.1% BSA, 0.01% Tween 20, 0.1 
mg/ml 4-(2-aminoethyl)-benzene sulfonyl fluoride, 0.1 mM iodoacetamide, 5 mM EDTA, 0.02% 
NaN3) at pH 5.4 (with sodium citrate) or pH 6.4 (2-(N-morpholino)ethanesulfonic acid, MES) in 
the presence of varying amounts of inhibitor peptides for 3 days at 37°C. The incubation time 
ensures the majority (>65%) of DR1 protein participates in the peptide binding reaction to reach 
equilibrium. Bound biotinylated peptide was detected using a solid-phase immunoassay and 
Eu2+-labeled streptavidin. Plates were read using a Wallac VICTOR counter (PerkinElmer 
Wallac). Data were fit to a logistic equation y = a/[1 + (x/x0)b]. IC50 values were obtained from 
the curve fit of the binding data and converted to KD values by using the equation KD = (IC50)/(1 
+ [bHA]/KD,bHA)) in which KD,bHA was set equal to 57.8 nM at pH 5.4 and 77.6 nM at pH 6.4 on 
the basis of the results of the direct binding of bio-HA peptide to DR1. Each point represents the 
mean and SD of three independent experiments performed in triplicate. Because pMHCII 
binding represents a multistep reaction, the IC50 for a competitive binding assay may not be 
directly proportional to the KD (14). Although this can be offset by long incubations relative to 
half-life, we study low affinity peptides where half-lives are impossible to determine. Therefore, 
the values of affinity reported herein should be considered as apparent KD values.
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Calculation of cooperative effects
We view cooperativity in pMHCII folding as the enhancement in binding or dissociation 
that arises in a second (or subsequent) interaction as a result of the primary interaction (8). This 
definition has been used by others in the context of protein folding or ligand binding (10, 15).
We used a multiple substitution strategy previously used to identify interacting partners during 
protein folding (3, 9). To normalize the t1/2 and KD values of a given pMHCII complex, we define 
the effect of each substitution as the ratio of the substituted measurement over that of the 
DR1/wild-type (wt)HA value (At1/2 for stability or AKD for affinity). Normalization of the 
measurements to that of the DR1/wt HA complex also allows for comparison of cooperativity 
measures in stability, which is measured directly, and affinity, which is measured indirectly.
For calculating cooperativity, the effect of multiple substitutions is measured directly 
(observed value). The expected value for a combination of substitutions is calculated as the 
product of the individual substitutions [e.g., At t1/2 x,y= (At1/2,x) x (At1/2,y)]. For peptides with three 
substitutions, the expected value would be the product of all the different substitutions [e.g., At1/2 
x,y,z= (At1/2,x) x (At1/2,y) x (At1/2,z)]. The cooperativity is the ratio of the expected to observed (C = 
exp/obs) values for either At1/2 or AKD. A value of 1 for the ratio of expected/observed indicates 
no cooperativity, for it would suggest independent energetic contribution in binding and/or 
release from each substitution. Cooperativity is evidenced when the ratio of expected/observed is 
not equal to 1.
2.4 Results
To test the effect of DM on cooperativity of the pMHCII interaction, thus structural 
flexibility, mutations were made at P1, P2, P4, and P7 position. The peptide generated via cycle 
mutation applied to the sequence of the HA305 -318 peptide are reported in Table 2.1. For the P1 
position, it has been previously shown that changing P1 to Val decreases the stability of the 
DR1/HA complex in the presence of SDS (16). Glu at P4 instead of Gln is expected to 
destabilize the formation of an H-bond with DR1 Gln9, whereas Arg introduces a basic residue 
at a position that prefers acidic side chains. Structural modeling revealed that two of these 
substitutions could potentially interfere with formation of H-bonds normally observed in the 
HA/DR1 structure. Indeed, the P2 and P7 Asp substitutions are located at positions in the 
peptide/DR1 interface in which rotation of the side chain around the a-carbon can directly 
destabilize H-bonds to the peptide backbone. Alternatively, these substitutions may indirectly
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lead to destabilization by facilitating solvent entry into the binding groove. Each substitution 
would provide an interaction sufficient for the formation of the complex, but when combined 
with substitutions at the other positions could reveal a measureable cooperativity during the 
interaction.
Cooperativity is a measurement of the flexibility when peptide binds to MHCII. During 
previous experiments in the absence of DM at pH 7.4, cooperativity was shown to contribute to 
complex stability (8). To determine the effect of DM on the energetics of the complex, we 
examined complex stability by determining the dissociation rate at both pH 6.4, Figure 2.1, and 
at pH 5.4, Figure 2.2. The individual data points of Figure 2.1 and 2.2 represent the mean t1/2 of 
three independent experiments, the individual peptide t1/2 values can be seen in Table 2.2. Each 
individual substitution resulted in small effects on the dissociation rate, except the P1V 
substitution, and the multiple substitutions had variable effects. These results are different than 
what is observed in the absence of DM as can be seen in Table 2.3, where the general trend is 
that DM shortens the t1/2 and this is more noticeable at the lower pH where DM is more active 
(17). To test the relative effect of peptide release, each singly substituted complex was calculated 
with respect to the stability of the unsubstituted DR1/HA complex. If the contribution of each 
substitution to complex stability were independent, then the effect of multiple substitutions 
would equal the product of their individual effects on stability. The ratio of observed to expected 
stability gives the cooperativity. In Figure 2.3 we show that cooperative effects are larger at 
pH 5.4 than at pH 6.4, although the R2 values show that the curve fitting is not the best 
representative for the cooperativity data, yielding an R2 = 0.471 at pH 5.4 and R2 = 0.251 at pH 
6.4. This trend is unexpected, since we would have predicted a different trend in the 
cooperativity compared to t1/2 plot. Several explanations for this deviation might be that, the 
short t1/2 for P1V could disrupt some of the multiple V substitutions of cooperativity; another 
could suggest that there are more structural conformations occurring during dissociation than 
what we were expecting. So we decided to calculate cooperativity on peptide binding, which are 
derived at equilibrium.
To assess the effect of DM on peptide binding, equilibrium-based competitive binding assays 
were completed at pH 6.4, as seen in Figure 2.4, and pH 5.4 reported in Figure 2.5. From the 
curve fits it is possible to determine the IC50 of each substituted peptide, which can be converted 
into a relative binding affinity (KD) by using the Cheng-Prusoff equation as described in the
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methods. There were two peptides P1,2,4 VDR and P1,2,4,7 VDEG that lost binding capabilities 
at pH 5.4. The relative KD values that were calculated from these figures are reported in Table 
2.2. From these values cooperative effects on peptide binding for multiple substituted peptides 
can be determined as the ratio between the observed KD (normalized over KD of wt HA peptide) 
and the expected normalized KD, which is calculated by multiplying the normalized KD from 
individual substitutions. Each point on Figure 2.4 and 2.5 was the result of the mean of three 
independent experiments, and error bars were the standard deviation of these three experiments 
from the mean. Compared to the peptide affinities in the absence of DM shown in Table 2.3, DM 
decreases the value of KD and this has implications for the stability of the complex (17).
The results of the cooperativity can be seen in Figure 2.6. The plot shows that as the pH 
decreases the slope of cooperativity is smaller. The fit of cooperativity compared to binding 
affinity at pH 5.4 has a slope of 0.772 with an R2 of 0.927, while the fit for pH 6.4 has a slope of 
0.898 with an R2=0.975. These results indicate that cooperativity is reduced in the presence of 
DM, and that this effect increases as the pH lowers, indicating that this is a DM-dependent 
phenomenon.
2.5 Discussion
Despite its importance in epitope selection, the mechanism of DM-mediated peptide 
exchange remains unclear. In this work, we analyze DM activity under the hypothesis that its 
action affects the structural flexibility involved in the pMHCII interaction. To test this hypothesis 
we adopted a multiple substitution strategy, previously described for the study of cooperative 
interactions in protein folding (15). Through this approach, one can construct a series of higher 
order mutant cycles to analyze the impact of different peptide substitutions relative to the wt HA 
sequence on complex energetics. We have adopted such a method in the case of intrinsic peptide 
binding to and release from DR1 (8, 18) and we have used it with a limited subset of peptides in 
the presence of DM to explore the impact of a specific DR1 mutation on DM function (19). Here 
we extend such studies to a broader library of peptides carrying a different set of mutations and 
we perform release and binding assays at two pH conditions to probe the impact of DM on 
cooperative effects, and thus system flexibility. We found that DM activity decreases cooperative 
effects in peptide binding, and such an effect is magnified at more acidic conditions, in keeping 
with the known pH-dependence of DM function.
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The crystallographic studies of pMHCII complexes have been important to infer general 
structural principles of peptide binding (6). However they indicate a stereotypic structure for 
these proteins, whereas biochemical data suggest the existence of alternate conformers as a 
function of pH and presence of peptide. Investigations aimed at better understanding which 
regions of the MHCII are involved in changes upon binding indicate that the a-subunit 310 helical 
region and the adjacent extended strand, the P2 Ig-like domain, and the pronounced kink in the 
P-subunit helical region P62-71 are the most subject to conformational heterogeneity, also for the 
bound state (20). Evidently, MHCII proteins have a degree of structural flexibility that can affect 
the interaction with the peptide and possibly decide the structure of the resulting complex, a 
feature not readily evident in the crystal structures. Such flexibility is evidenced by 
thermodynamic properties, such as cooperativity and entropy-enthalpy compensation, and we 
have shown that DM interacts with complexes where the formation is associated with smaller 
entropic penalty and greater conformational lability, as described in our paper attached in the 
appendix (9). The current data provide an important insight into the mechanism of DM function, 
indicating that the outcome of the DM/pMHCII interaction is to favor the formation of 
complexes with limited structural flexibility (reduced cooperativity); moreover there is no 
preferential position along the peptide binding groove determining the magnitude of DM effect.
Whereas the interpretation of the binding assays appears straightforward, DM-mediated 
dissociation experiments show cooperativity trends that would not be easily derived by inference 
from the intrinsic dissociation studies. Indeed, off-rates of the multiple substituted peptides were 
slower than expected at pH 6.4, but particularly at pH 5.4. This observation seems to conflict 
with the increasing cooperativity measured for multiple substituted peptides as a result of DM 
activity and decreasing pH. One explanation for this apparent paradox is that DM may affect 
peptide on-rate as well as peptide release, thus the overall cooperative effect observed at the 
equilibrium in our binding experiments reflects DM action on both directions of reaction. With 
this regard, a recent work has been published showing that the association of peptides with 
MHCII in the presence of DM have faster kinetics than the MHCII alone, and presented multiple 
possibilities for the on-rate as well as the off-rate (21).
A second explanation for the different cooperativity trends may relate to the various 
partial reactions occurring during the release assays monitored in real time, which are not evident 
in the binding assays measured at equilibrium, as they are a function of state. During DM-
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mediated off-rates, it is possible that the addition of unlabeled competitor peptide in excess 
exerts an effect on complex kinetic stability in the presence of DM, and such effect is 
independent from the characteristics of the bound peptide. Moreover, as FAM-peptide is released 
from DR and substituted by unlabeled competitor, new complexes are formed, which might 
interact with DM; the activity of DM on unlabeled peptide/DR complexes, may cause the 
changes in DM/FAM-peptide/DR stoichiometry over time, affecting the contribution of DM to 
FAM-peptide release.
On the basis of the current results, and previously published observations, we propose a 
model of DM mechanism where DM interacts preferentially with complexes featuring a 
significant conformational lability, in particular in the aforementioned regions, reflecting the 
thermodynamic mechanism adopted by peptide and MHCII to form a complex. Upon interaction, 
DM would form an intermediate with MHCII that binds peptide with faster kinetics than MHCII 
in the absence of DM (21). Such an intermediate would facilitate peptide exchange, consequently 
accelerating the identification of those ligands, which can form a complex with limited structural 
flexibility. Once a complex with reduced conformational stability is formed it would dissociate 
from DM and relocate to the membrane for T cell recognition.
Although we think that the above model provides a solid explanation for the observations 
reported by our and other groups, other questions about DM mechanism are still open. For 
instance, it is not clear how a DM-pMHCII intermediate resolves to generate an exchanged 
pMHCII complex. We still do not know whether the exchanging peptide competes with the pre­
bound mainly via P1 pocket, or through interactions throughout the entire peptide binding 
groove. Our distributed model of peptide binding would favor the latter, but it is possible that 
this is a peptide or allele phenomenon. Moreover, it would be important to understand how 
peptide sequence determines the ability to be exchanged onto MHCII during antigen 
presentation. We have proposed a model involving a tetramolecular DM-MHCII-two peptide 
intermediate based on kinetics and spin-label studies (22), however further analysis is required to 
fully describe this important step of the epitope selection process.
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Figure 2.1 Fluorescence Polarization Dissociation at pH 6.4 
Dissociation rates of pMHCII complexes. Data are expressed as the 
fraction of complex remaining relative to t = 0. Reactions were 
performed in triplicate, and data series represent one of three 
independent experiments. The protocol was changed part way through 
the pH 6.4 experiments, which is why data for wt HA, D, VEG, VRG 
extend only to 580 minutes on this graph.
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Figure 2.2 Fluorescence Polarization Dissociation at pH 5.4 
DM-mediated dissociation rates of pMHCII complexes at pH 5.4. Data 
are expressed as the fraction of complex remaining relative to I = 0. 
Reactions were performed in triplicate, and data series represent one of 
three independent experiments.
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Figure 2.3 Cooperativity of Peptide Dissociation 
Natural log (ln) plot of cooperativity (observed/expected ti/2) vs. 
DM-mediated dissociation rate for each DR1/peptide complex 
tested at pH 6.4 (gray dot, dashed lines) and at pH 5.4 (white dots, 
solid lines). Since we defined cooperativity C as the ratio of the observed to expected values for 
At1/2 , and tm  is directly proportional to stability, the cooperative effect is negative if 0<C<1, 
while if C>1 the cooperative effect is positive. In the ln plot, positive cooperativity in stability is 
indicated on the y-axis by values >0 and negative cooperativity by values <0. Lines indicate the 
fit of the data to a linear regression (pH 6.4: slope = 0.469, R2=0.251; pH 5.4: slope 0.797,
R2=0.471).
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Figure 2.4 Competitive Binding Assay at pH 6.4 
Competition binding analysis of P1, P2, P4 and P7 
substituted HA peptide variants to DR1. Data represent the 
mean and SD of three independent experiments. Lines 
indicate the fit of the data to a logistic equation. The KD 
values for each peptide are reported in Table 2.2.
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Figure 2.5 Competitive Binding Assay at pH 5.4 
Competition binding analysis of P1, P2, P4 and P7 
substituted HA peptide variants to DR1. Data represent the 
mean and SD of three independent experiments. Lines 
indicate the fit of the data to a logistic equation. The KD 
values for each peptide are reported in Table 2.2.
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Figure 2.6 Cooperativity of Peptide Binding
Natural log (ln) plot of cooperativity (observed/expected Kd) vs. DM-mediated dissociation 
constant for each DR1/peptide complex tested at pH 6.4 (gray dot, dashed lines) and at pH 5.4 
(white dots, solid lines). Since we defined cooperativity C as the ratio of the observed to 
expected values for A Kd, and Kd is inversely proportional to binding affinity, the cooperative 
effect is positive if 0<C<1, while if C>1 the cooperative effect is positive. In the ln plot, positive 
cooperativity in stability is indicated on the y-axis by values <0 and negative cooperativity by 
values >0. Lines indicate the fit of the data to a linear regression (pH 6.4: slope = 0.898, 
R2=0.975; pH 5.4: slope = 0.772; R2=0.927).
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2.7 Tables
Table 2.1 List of Amino Acid Substitutions Applied to HA305-318
Shown here is the wt HA305-319 sequence (PKYVKQNTLKLAT, with the G at the N-terminal 
added for labeling purposes). P i, P2, P4, P7 refer to the peptide positions interacting with the 
DR1 pockets lining the binding groove. Underneath the original sequence the amino acids 
adopted for the cycle mutation are indicated. These substitutions lead to 22 unique peptides.
P1 P2 P4 P7
G P K Y V K Q N T L K L A T
V D E G 
R
Table 2.2 Binding Affinity and Half-life Values
Affinity and dissociation rate of substituted peptide/HLA-DRi complexes. N/A: not available.
Peptide 6.at 5.at t1/2 (mins) at 6.4 t1/2 (mins) at 5.4
wt HA 82 121 12100 5000
P1 V 125 291 191 55
P2 D 129 162 696 189
P4 E 72 74 6000 4973
P4 R 194 441 404 150
P7 G 83 143 2174 411
P2,7 DG 975 3,969 N/A N/A
P2,4 DE 388 396 2927 4111
P2,4 DR 3,718 12,970 11400 28600
P1,2 VR 15,620 146,500 22 42
P1,2 VD 5,968 24,500 97 18300
P1,4 VE 632 673 128 81
P4,7 EG 212 287 1870 775
P4,7 RG 2,399 14,400 666 58
P1,7 VG 2,032 13,650 76 28
P1,2,4 VDE 121,200 33,330 N/A N/A
P1,4,7 VEG 15,590 29,020 202 2815
P2,4,7 DEG 7,173 10,520 N/A N/A
P1,4,7 VRG 5,683 61,420 55 30
P2,4,7 DRG 149,200 3,258,000 N/A N/A
P1,2,7 VDG 481,400 1,433,000 N/A N/A
P1,2,4 VDR 1,159,000 No binding N/A N/A
P1,2,4,7 VDEG 2,954,000 No binding N/A N/A
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Table 2.3 Comparison to Data in the Absence of DM
DM+/ DM- for both affinity and dissociation rate of substituted peptide/HLA-DR1 complexes
N/A: not available.
Peptide Kd at 6.4 Kd at 5.4 t1/2 (mins) at 6.4 t1/2 (mins) at 5.4
wt HA 2.21 2.89 0.302 0.014
P1 V 0.91 2.16 0.130 0.035
P2 D 1.34 1.55 0.190 0.026
P4 E 1.01 1.57 0.001 0.029
P4 R 2.95 2.64 0.357 0.103
P7 G 1.11 1.03 0.237 0.032
P2,7 DG 3.57 12.28 N/A N/A
P2,4 DE 2.16 1.51 0.722 0.201
P2,4 DR 5.17 5.45 0.829 3.57
P1,2 VR 2.90 16.40 0.655 1.02
P1,2 VD 1.40 3.80 0.487 20.15
P1,4 VE 2.12 2.00 0.138 0.035
P4,7 EG 2.43 1.95 0.265 0.044
P4,7 RG 5.30 7.05 0.396 0.316
P1,7 VG 3.69 9.86 0.419 0.176
P1,2,4 VDE 6.42 6.22 N/A N/A
P1,4,7 VEG 2.23 4.05 0.466 1.14
P2,4,7 DEG 1.49 6.24 N/A N/A
P1,4,7 VRG 3.79 8.80 0.362 0.258
P2,4,7 DRG 2.87 27.26 N/A N/A
P1,2,7 VDG 2.97 9.69 N/A N/A
P1,2,4 VDR 3.37 N/A N/A N/A
P1,2,4,7 VDEG 2.00 N/A N/A N/A
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Chapter 3 Conclusion
3.1 The Impact of DM on the Outcome of Epitope Selection
The response that develops from T cells recognizing epitopes bound to MHC is a 
significant part of the immune defense against pathogens. Exogenous antigen presentation within 
APC is a well-understood system, with the exception of the exact mechanism of how DM 
regulates the binding of peptides to MHCII. The aim of the research presented here was to 
determine the function of DM and its impact on the process of peptide binding to MHCII. 
Understanding the basic action of DM has the potential to aid in the prediction of the epitope 
selection process. During the course of these experiments, the hypothesis was tested that DM 
functions by favoring the survival of peptide/MHCII complexes in which structural flexibility is 
limited. To confirm this hypothesis, cycle-mutated HA305 _ 318 peptides were examined using 
fluorescence polarization to test peptide dissociation and competitive binding assays to examine 
peptide binding. Cooperativity was calculated as a proxy for structural flexibility in the system in 
the attempt to develop insights into DM activity.
The results of peptide dissociation experiments in the presence of DM gave an 
unexpected measurement of cooperativity. Analysis of off-rate data for individual peptides 
however, revealed that DM decreased the t1/2 as compared to experiments where DM was absent, 
also in the case of multiple-substituted peptides which appear to unfold more slowly than what 
expected on the basis of single substitutions. The measurements from peptide dissociation do not 
provide a clear insight into DM action; this result could be due to the likelihood that there are 
multiple states of binding of the peptide to MHC, with different susceptibility to DM (1). An 
additional reason for the unanticipated results of release experiments is the possible sequestration 
of DM by complexes formed by the unlabeled competitor peptide, once the latter displaces the 
originally bound fluorescently labeled peptide. Although the kinetics of this interaction is not 
monitored by the FP signal, it affects the kinetics of the fluo-peptide release from MHCII by 
altering the complex:DM ratio. With this regard, a recent work has been published showing that 
the association of peptides with MHCII in the presence of DM have faster kinetics than the 
MHCII alone, and presented multiple possibilities for the on-rate as well as the off-rate (2). On 
the other side, the competitive binding assays measured at the equilibrium indicated that 
cooperativity is reduced in the presence of DM. Since cooperativity is a measurement of 
flexibility, we interpret these observations as an indication that DM is more likely to act on
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pMHCII complexes that have a larger conformational lability, resulting in the survival of less 
flexible complexes. However, further work is needed to determine a more exact model, which 
may reconcile the binding data with the release experiments.
These sets of experiments provided new information on the mechanism of DM action during 
the peptide binding process. A better model of peptide binding has implications on the general 
knowledge of the typical pathogen infection, and it would also provide improved options for 
peptide-based vaccinations. The in silico approach of creating peptide binding prediction 
algorithms is promising, but shows significant shortcomings in accuracy (3). A more detailed 
understanding of DM action would greatly help the process of predicting peptide binding to 
MHCII. We expect to gain decisive insights in DM activity by coupling isothermal titration 
calorimetry (ITC) analysis of the DM-MHCII-peptide interaction with structural analysis of 
complex flexibility with high-resolution spectroscopy (EPR or TR-FA).
3.2 Future Directions
Our results indicate that the presence of DM alters cooperativity, thus system flexibility, 
and affects complex formation or peptide dissociation by increasing the energetic threshold for 
stable binding. The next step is to determine how DM impacts the thermodynamics of peptide 
binding seeking confirmation for our model of DM activity. We propose to measure the 
thermodynamics of the peptide/MHCII (pMHCII) binding reaction in the absence and in the 
presence of DM, deconvoluted in enthalpic and entropic contributions, by ITC. A subset of 
peptides investigated by competitive binding and off-rate experiments will be selected in order to 
correlate changes in kinetic and binding behavior to any changes in thermodynamic mechanism 
of binding. The results of the thermodynamic analysis will provide an insight into how DM 
changes the energy of the system.
It is possible that DM will alter peptide binding by increasing the energetic threshold for 
stable binding through changes in the enthalpic and entropic components of pMHCII complex 
formation. To test this hypothesis, we will perform a thermodynamic analysis of pMHCII 
complexes selected on the basis of the preliminary binding and off-rate analysis. ITC will allow 
us to accurately measure the dissociation constant of the complexes, as well as the involved heat, 
which comprises the enthalpy of binding of the exothermic binding process. Entropic 
contribution can be easily derived by difference. On the basis of our pilot study, ITC analysis 
will be performed in triplicates using a DR1 protein concentrations in the calorimeter cell of ~5
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pM and 3-fold excess DM concentrations, whereas peptide concentrations in the syringe will be 
~50 pM. We will need to maintain a relative small concentration of DR in the cell to prevent DR 
aggregation, which would introduce a significant error in the measurement of the other 
interactions. ITC injection volume will be 2 pl, and injections will be performed over 10 seconds 
spaced 180 seconds apart to allow for a complete return to baseline (4). Analysis of the data will 
yield binding enthalpy and dissociation constant. Enthalpy represents the heat energy of reaction; 
this term is negative when a binding interaction is formed and heat is released. The entropic 
contribution is a measurement of randomness of the system; this term is positive in 
correspondence of an increased structural flexibility of the system or upon reactants desolvation.
Since enthalpy is a state property, the calculated overall enthalpy of the ternary complex 
from any of the possible pathways should give identical values within experimental error. We 
will perform titration experiments with different protein mixtures in the calorimeter cell and the 
syringe to precisely identify the effect of DM on peptide/MHCII complex formation. Because 
DM/pMHCII binding is thought to be associated with the disruption of interactions between a 
specific stranded region of the MHCII alpha-chain and the peptide backbone, one could expect 
only the enthalpic contribution to be altered, especially if there is no significant modification of 
entropy between the DM-unbound and the bound state. A more likely situation is that the 
presence of DM prevents HLAII from providing sources of interaction to complex formation, but 
also decreases complex flexibility, therefore affecting both enthalpic and enthropic components 
of free energy decrease. Either outcome will be very informative as to how peptide binding 
occurs in the presence of DM.
An important technical consideration is that when studying complex protein interactions 
by ITC, a single titration may not be sufficient to sample the shape of the binding isotherm and 
may not allow derivation of the binding parameters. Therefore, many titration experiments will 
be combined to explore the shape of the isotherm of heat as a function of three protein 
concentrations. SEDPHAT, software available on the NIH website, will be used to analyze the 
multiple ITC titration experiments and derive the thermal profiles of ternary macromolecular 
interactions.
Integrating the thermodynamic data with structural observations will be key to outline a 
comprehensive model of peptide binding to MHCII and DM activity, which will greatly support 
epitope prediction and development of peptide-based vaccines.
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Abstract
Peptides bind Class II Major Histocompatibility Complex molecules (MHCII) through a 
thermodynamically non-additive process consequent to the flexibility of the reactants. Currently, 
how the specific outcome of this binding process effects the ensuing epitope selection needs 
resolution. Calorimetric assessment of binding thermodynamics for HA306_3 19 peptide variants to 
the human MHCII HLA-DR1 (DR1) and a mutant DR1 reveals that peptide/DR1 complexes can 
be formed with different enthalpic and entropic contributions. Complexes formed with a smaller 
entropic penalty feature circular dichroism spectra consistent with a non-compact form, and 
molecular dynamics simulation shows a more flexible structure. The opposite binding mode, 
compact and less flexible, is associated with greater entropic penalty. These structural variations 
are associated with rearrangements of residues known to be involved in DM binding, affinity of 
DM for the complex, and complex susceptibility to DM-mediated peptide exchange.
Thus, the thermodynamic mechanism of peptide binding to DR1 correlates with the structural 
rigidity of the complex, and DM mediates peptide exchange by “sensing” flexible complexes in 
which the aforementioned residues are rearranged at a higher frequency than in more rigid ones.
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Introduction
MHC class II (MHCII) molecules are transmembrane heterodimeric proteins expressed on the 
surface of APCs and are fundamental in initiating or propagating an immune response by 
presenting antigenic peptides to CD4+ T lymphocytes. Newly synthesized MHCII molecules are 
transported from the endoplasmic reticulum to the MHCII compartments (MIIC) as multimeric 
complexes with the chaperone protein invariant chain (Ii). Ii stabilizes the nascent MHCII and 
prevents the binding of other peptides that are present in the endoplasmic reticulum (1). Upon 
arrival in the MIIC, the Ii molecule is cleaved primarily by cathepsin S (and to a lesser extent by 
cathepsins L, V, F and K) (2), leaving a peptide fragment termed class II-associated invariant 
chain peptide (CLIP) in the MHCII binding groove. For most MHCII alleles, CLIP is released by 
the action of the non-classical MHCII molecule HLA-DM (DM) to allow antigenic peptides to 
bind MHCII (3, 4). The role of DM exchange is not limited to CLIP, as it can catalyze the 
exchange of antigenic peptides to select for a stable peptide/MHCII (pMHCII) repertoire (5).
The crystal structures of peptide-complexed MHCII molecules have shown that peptide 
binding relies on interactions between pockets lining the class II groove and side chains of the 
peptide, and on a series of hydrogen bonds between non-polymorphic MHCII side chains and the 
peptide backbone (6). The primary pockets are indicated as P1, P4, P6 and P9, with P1 being the 
pocket located at the N-terminal side of the complex, and the individual interaction is allele- 
specific, due to the size and the hydrophobicity of the pocket. The encapsulation of bulky 
hydrophobic side chains of the peptide into the P1 pocket of the human MHCII HLA-DR (DR) is 
considered a requirement for stable peptide binding (7, 8), and is regarded as a major source of 
binding energy (9, 10).
Due to its role in the generation of the MHCII-restricted peptide repertoire and in 
stimulating the presentation of immunodominant epitopes, DM activity has been the focus of 
intense investigation. DM would function as an enzyme, facilitating the release of the peptide 
bound to MHCII and accelerating peptide exchange (11). However, the susceptibility to DM 
action varies among peptides, and significant efforts have been made to identify the features of a 
pMHCII complex that make it a target for DM. In keeping with a recently published review, we 
think that significant insights gained particularly in the last decade suggest two possible, non- 
mutually exclusive factors determining DM-susceptibility (12). The first model indicates that the 
occupancy state of the P1 pocket plays a major role in determining DM-susceptibility. For
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instance, it has been shown that DM specifically binds DR2 variants in which the N-terminal site 
of the complex was emptied (13), and the crystal structure of a covalent DM-DR1 complex has 
been resolved in which the antigen was a covalently linked peptide lacking three N-terminal 
residues, thus leaving the P1 pocket vacant (14). The second model proposes that DM- 
susceptibility correlates with the pMHCII complex undergoing conformational rearrangements. 
In support of this model are SDS-based studies of complex stability (7, 15) and, more recently, 
the analysis of aF54-substituted DR1 molecules bound to a high-affinity peptide (16). This latter 
study showed that these mutants are more susceptible to DM-mediated peptide release than 
wtDR1, they feature increased affinity for DM, and increased peptide vibration, especially in the 
H-bonding network at the N-terminal site of the complex. The resolved structure of HLA-DO 
(DO) bound to DM points again to the possibility that conformational variation of the MHCII, in 
particular alterations in the a-subunit 310 helix and adjacent regions are responsible for tight 
binding to DM (17). In the same vein, we have shown that MHCII molecules loaded with 
different peptides sharing a Y at P1 can assume two conformations that are either susceptible or 
resistant to DM-mediated peptide release. The generation of the susceptible isomer appears to be 
correlated to the affinity of the bound peptide for DR or can be triggered by adding a second 
peptide to a reaction containing only the resistant form (18).
The evidence that peptides able to fill the P1 pocket are potential DM targets leaves the 
question open as to which complex features might be responsible for DM-susceptibility, and 
whether these features are somehow related to the peptide sequence. Here we show that DM- 
susceptibility is determined by interactions throughout the peptide binding site, in that the 
thermodynamic mechanism adopted by a pMHCII dyad for binding, irrespective of P1 
occupancy state, is reflected in the overall conformation and residual flexibility post-complex 
formation. In turn, these structural features correlate with DM-mediated peptide release. This 
resolves the question of epitope prediction to one of predicting the structural features of the 
complex.
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Materials and Methods
Peptide synthesis
Peptides derived from the sequence GPKYVKQNTLKLAT, representing residues 306-319 of 
the hemagglutinin protein from influenza A virus (H3 subtype), are described in Table A.1. The 
N-terminal Gly facilitated labeling. Side chains in the HA peptide are numbered relative to the 
P1Y residue (19). N-terminal labeling with FAM (Molecular Probes, Life Technologies 
Corporation) was performed on the resin before deprotection, and then peptides were cleaved 
and purified by HPLC and confirmed by MALDI-TOF mass spectrometry (Protein Nucleic Acid 
Facility, MCW).
Expression and purification o f recombinant soluble DR1 protein
Recombinant soluble empty (peptide free) DR1 was produced and purified by ioGenetics 
(Madison, WI) from a stably transfected CHO mammalian cell line with a proprietary retroviral 
vector transduction system essentially as described for antibodies (20). The genes code for 
proteins of 192 (a) and 198 (b) residues, which terminate just before the beginning of the 
predicted transmembrane spans (residues 193-197 and 199-203 respectively). The vector was 
designed to generate a poly-His tag at the C-terminus of the expressed protein. DR-expressing 
clones were selected and expanded. His-tagged DR1 proteins were purified with a His-trap HP 
column coupled to an AKTAFPLC chromatography system, and buffer exchanged into PBS (7 
mM Na+/K+ phosphate, 135 mM NaCl, pH 7.4) using centrifugal ultra-filtration (Amicon). 
Soluble FLAG-tagged DM was isolated from a stably transfected Drosophila S2 cell line as 
described (21). To avoid contamination with FLAG peptide, DM elution from the resin was 
performed with 0.1 M glycine HCl, pH 3.5. Both DR1 and DM proteins were purified and buffer 
exchanged into K/Na-phosphate buffer (1.47 mM KH2PO4, 8.1 mM Na2HPO4, 135 mM NaCl, 
2.7 mM KCl, pH 7.4) using centrifugal ultra-filtration (Amicon). Purity (>95%) was confirmed 
by SDS-PAGE stained with GelCode Blue Stain Reagent (Pierce). DR1 proteins were quantified 
by measuring the UV absorbance @ 280 nm using an E280 of 45,494 M-1 cm-1 before use as 
calculated with the Expasy ProtParam tool (54).
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Generation and expression o f  ^ 81-mutated DR1 molecules
Plasmids encoding truncated forms of the HLA-DRa and DRP*(0101) genes were the gift of Dr. 
Lawrence Stern (U. Mass. Medical School) (22). Position 81 His of the P chain was mutated to 
Asn through the use of the QuikChange site-directed mutagenesis kit (Stratagene) and the primer 
5‘:CCAACCCCGTAGTTGTTTCTGCAGTAGGTGTC:3‘. The mutation was confirmed by 
sequencing, and wt a and mutant P plasmids were cotransfected into CHO cells for subsequent 
production by ioGenetics as indicated above. SDS-PAGE analysis of purified P81mut and DR1 
proteins revealed no significant differences in migration or purity.
Isothermal titration calorimetry (ITC)
Titration calorimetry was carried out with a Microcal ITC200 (GE Healthcare). Analysis was 
performed at least in triplicate with peptide in the syringe and DR1 in the calorimeter cell at 25 
°C, pH 7.4. Starting protein concentration in the calorimeter cell was 5 pM, whereas peptide 
concentration in the syringe was 50 pM. ITC injection volumes were 2 pl, and injections were 
performed over 10 s at a steering speed of 500 rpm spaced 180 s apart to allow for a complete 
return to baseline. Dilution heats were measured by titrating 50 pM of peptide from the syringe 
into the cell containing only buffer. Data were processed and integrated with Origin software. 
Single data sets were fit to a single site ITC binding model, using a baseline offset parameter to 
account for heat of dilution. The first data point was excluded from analysis due to dilution 
across the injection needle tip.
Peptide/MHCII (pMHCII) complex generation
pMHCII complexes were formed by incubating 1 mM MHCII protein with a 10-fold molar 
excess of either unlabeled or FAM-labeled peptide (depending on the experiment) in PBS (pH 
7.4) and protease inhibitors for 16-18 h @ 37 °C. pMHCII complexes were then purified from 
unbound peptide with a Centricon-30 spin filter that had been pre-incubated with 25 mM MES 
(pH 6.4). Purified complexes were then quantified by reading the UV absorbance @ 280 nm, 
factoring in an E280 of 1280 M-1 cm-1 for the Y residue and 10846 M-1 cm-1 for the fluorescein 
present in the bound peptide. The latter measurements would add to the extinction coefficient 
endogenous value reported above.
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Circular dichroism spectroscopy (CD)
For CD analysis, empty and peptide-loaded complexes were exchanged into 5 mM sodium 
phosphate/5 mM sodium acetate buffer, pH-adjusted with concentrated stocks of HCl and 
filtered to a final concentration of 3.5 pM (~0.2 mg/ml). Dichroism measurements were made 
using a 1-mm path length cuvette on a Jasco J-720 spectrophotometer. Wavelength scans were 
obtained using 1.5-nm bandwidth, constant 10 °C temperature, and 1-nm sampling with a 5- 
second dwell time per point. All experimental scans were adjusted for background signal by 
subtracting out the signal from a dialyzing buffer scan.
Thermal denaturation
Thermal stability data was obtained by monitoring the CD signal at 204 nm while the 
temperature was increased from 10 °C to 90 °C, using 1 °C intervals, 1-minute equilibration 
time, 1-minute dwell time at each temperature, and 2-nm bandwidth. For each unfolding 
transition, the midpoint temperature Tm was determined as a peak in the first derivative function 
of the unfolding curve, and also separately by curve-fitting to a seven-parameter function that 
describes a two-state transition (23, 24):
(i9f  -  du) +  T ( m f  -  m u)
^ — (^M + m u T) +
.1 +  el
where 9u and mu describe the slope and y-intercept of the unfolded state baseline; 9f and mf 
describe the slope and y-intercept of the folded state baseline; Tm is the midpoint of the transition 
(where AG = 0); ACp is the heat capacity change upon unfolding; and AH is the enthalpy of 
unfolding at the Tm. The thermodynamic values derived in this analysis are likely to depend on 
the concentration at which the equilibrium is measured, and therefore only holds for the 
concentration ranges tested (0.1-1 mg/ml) (24). The relationship of the unfolding transition to an 
irreversible denaturation that occurs in the same temperature range was investigated by recording 
the dependence of the midpoint temperature on the rate of the scan for overall scan rates 0.33 
°C/min to 1.33 °C/min. As described previously for DR1, only a slight dependence was observed 
over the rates tested, indicating that the two-state approximation can be used at the experimental 
scan speeds (8, 25).
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Molecular dynamics (MD) simulation
The MD simulation was performed with the software package NAMD (26) using the 
CHARMM22 force field with an explicit water model and all simulations were carried out at 
constant temperature (298 K), pressure (1 atm). All molecular graphics images were generated 
using the Visual Molecular Dynamics (VMD) software (27). The structure of the MHC class II 
molecule in complex with peptide epitope (PDB: 1DLH) was taken from the Protein Data Bank. 
The complexes formed by HA-substituted peptides and DR1 or P81mut were prepared by 
applying the appropriate mutations within the sequence of the wt peptide with the VMD mutator 
plugin, version 1.3.
The peptide/MHC complex was solvated in a box of transferable intermolecular potential 
(TIP) water with at least 10 A distance between protein and the boundary of the water box. The 
system was first minimized with 10,000 steps of steepest descent followed by 100,000 steps of 
conjugate gradient descent. The MD simulation time step was 2 fs, and trajectory was saved 
every 1 ps. The length of the simulation was determined by monitoring the convergence of 
various mechanical properties of the system. The simulation was stopped when the value for the 
RMSD did not fluctuate more than 3.0 from its average value during 2 ns. As previously 
indicated, when the simulation reaches an RMSD that oscillates around a constant value, it can 
be assumed the system has converged to a stable or a metastable structure. A twin range cut-off 
of 0.9/1.4 nm for van der Waals interactions was applied, and the particle mesh Ewald method 
was used to treat long-range electrostatic interactions. Constant temperature was controlled by 
Langevin dynamics, and pressure was maintained by using Nose-Hoover Langevin piston 
pressure control.
Surface plasmon resonance (SPR)
SPR experiments were performed on a Biacore 2000 instrument. Anti-FLAG antibody M2 for 
DM capture was immobilized on the CM5 sensor chip using standard amine coupling procedure. 
FLAG-tagged DM was diluted to 75pg/ml in 10 mM Sodium Acetate. 5000 RU of DM protein 
were immobilized on the anti-FLAG coated chip at a flow rate of 5-10 pl/min at 25 °C, and the 
surface was subsequently blocked with 1M 2-aminoethyl-sulfate and washed with 50 mM CAPS 
solution. Affinity experiments were performed by injecting the various pMHCII complexes in 
two fold dilutions and at seven concentrations from 8 mM and run over the DM surface at flow
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rate of 5 pl/min. The running buffer in all phases was composed of 10 mM sodium citrate pH 
5.5, 150 mM NaCl, 3 mM EDTA, and 0.05% (vol/vol) surfactant P20. PBS buffer, 0.05% 
(vol/vol) surfactant P20 was used for control experiments at pH 7.4. Regeneration of the DM- 
coupled surface was carried out by flowing 50 mM CAPS pH 11.5 for 30 s until a stable baseline 
was reached. Binding data were fit to a Langmuir binding model using BIAeval software.
Fluorescence polarization (FP) dissociation measurements
Intrinsic and DM-mediated peptide dissociation measurements were performed via FP, which 
quantifies the ratio between bound and free fluorophore-labeled ligand by measuring the 
tumbling speed of the fluorophore, as the speed is faster when the ligand is unbound. 100 nM of 
purified complexes generated as indicated above were incubated with 100-fold excess of 
unlabeled HA306_3 19 peptide and 3-fold excess DM where required. In past analysis we have 
shown that, in our system, a DM/complex ratio < 3 is not sufficient to promote peptide exchange. 
It was also reported that in the MIIC, the DM:MHCII ratio is 1:5 (28). Our observations might be 
affected by the 3D geometry of reaction, with respect to the planar situation of membrane-bound 
MHCII molecules; nevertheless the majority of published data relative to DM activity have been 
collected by using soluble DM in kinetic experiments. Reactions were performed at 37 °C in 50 
mM sodium citrate/sodium phosphate buffer at pH 5.4 and were covered with mineral oil to 
prevent evaporation. To avoid non-specific adherence of the protein, treated black polystyrene 
96-well plates were used (Corning), as indicated in ref. (29) and (33). Measurements were 
performed using a Wallac VICTOR counter (PerkinElmer Wallac) with the excitation l = 485 nm 
and emission l = 535 nm. Specific control groups included (a) protein only, (b) peptide only, and 
(c) buffer only, and were used for background correction. FP values were transformed in fraction
pp   p P f
of bound peptide with the equation: Pbound =  x-----free—, where FPx indicates the value of FP
! " b o u n d ~ ! "  f r e e
measured by the counter at t = x (minutes), FPfree indicates the value of FP relative to free 
peptide, and FPbound indicates the value of fluorescence polarization of the complex. We assume 
that the latter value coincides with the value of FP measured at t = 0 of the experiment, since we 
have shown that we are able to isolate pMHCII complexes with a bound MHCII/total MHCII 
ratio > 90% and bound peptide/total peptide > 97% (33). Fraction of bound peptide is then 
plotted against time and fit to a one- or a two-phase exponential function for t1/2 calculation. Each
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experiment was performed in triplicate, and the reported dissociation rate reflects the mean ± SD 
of three independent experiment
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Results
Peptide-MHCII dyads form complexes with different thermodynamic mechanisms.
In our past investigation of peptide binding to and release from MHCII we have observed by 
indirect approaches the occurrence of isothermal entropy-enthalpy compensation (iEEC) (30) 
and binding cooperativity (30-32), and we interpreted them as the thermodynamic epiphenomena 
of the system structural flexibility. Those experiments were performed with a panel of peptides 
derived from the sequence of HA306-319 via cycle mutation, and HLA-DR1 (DR1) or a mutant 
DR1 (P81mut), in which formation of the H-bond between the peptide backbone and the non- 
polymorphic His at position 81 of the P-chain (P81 H-bond) is inhibited by a H"N mutation. 
Among those sequences we identified a peptide, HASG, in which the combined effect of the 
P2V"S and P10A"G mutations resulted in a ~4 fold decrease of KD for DR1 as assessed in 
competitive binding assays (32, 33). Though HASG can still be considered a high-affinity 
binder, its intrinsic kinetic stability for DR1 and P81mut was found to be significantly decreased 
with respect to the wt sequence. Thus, we reasoned that this sequence would be particularly 
suitable to investigate the potential association among thermodynamic mechanism adopted for 
binding, structural conformation of the resulting complex, and susceptibility to DM action.
The thermodynamic parameters of the peptide binding reactions to DR1 and P81mut were 
derived by Isotheral Titration Calorimetry (ITC). The calorimetric isotherm of binding of peptide 
to MHCII illustrates an exothermic binding characteristic at 25 °C. The standard enthalpy change 
(AH°), dissociation constant (KD), and stoichiometry (n) and the standard error for each variable 
were derived on the basis of the one-site model fit of the peptide/MHCII complex (pMHCII) 
isotherm (Figure A.1). The AH°, KD, and n values of peptide binding listed in Table A.1 are the 
error-weighted mean values and the standard error of the mean for each variable from three 
repeated experiments. The standard errors of the mean for standard free energy decease (AG°) 
and standard entropy change (TAS°) were calculated using the standard error of the mean of the 
association constant (KA) and AH° by statistical error propagation method. Observed enthalpies 
derive largely as a consequence of changes in interatomic interactions (e.g., hydrogen bonds, van 
der Waals interactions, p-p interactions), in which the sign indicates that there is a net favorable 
(negative AH) redistribution of the network of interactions between the reacting species 
(including solvent). Hydrophobic interactions are related to the relative degrees of disorder in the 
free and bound systems and thus these interactions are reflected in the entropy change. The
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release of “bound” water molecules from the binding groove surface and the peptide to the bulk 
solvent is a source of favorable entropy (positive AS). A reduction in conformational states in 
either ligand or protein upon binary complex formation is entropically unfavorable (negative 
AS). All binding reactions are enthalpy-driven, however the measured overall entropic 
contribution differs, indicating that the restriction in conformational mobility occurring upon 
ligand binding varies as a function of the peptide. Indeed, in the case of HASG, binding to DR1 
is associated with a smaller entropic penalty as compared to HA, suggesting a more pronounced 
residual conformational mobility post-complex formation.
The analysis of b81mut binding is consistent with our observations derived with indirect 
methods (30). In the case of HA, the enthalpic contribution to binding free energy does not 
change significantly with the b81 H-bond disruption, whereas the entropic penalty is reduced 
with the consequence that binding to b81mut is favored as compared to DR1. Conversely, the 
inability to form the b81 H-bond for HASG has a greater impact on binding free energy, in that it 
cooperatively prevents formation of other interactions, with a significant reduction of the 
enthalpic component. For this latter complex, the entropic contribution is positive, indicating that 
reduction in conformational mobility upon binding is limited and it reflects predominantly a 
favorable desolvation-related entropy change.
These results show that formation of high-affinity (pMHCII) complexes (such as 
HA/DR1 and HASG/DR1) can be achieved with different enthalpic and entropic contributions, 
and they confirm that the impact of one specific interaction on binding (such as the b81 H-bond) 
depends on the overall energetics of the system.
Thermodynamics ofpMHCII complex formation is associated with complex secondary structure. 
To investigate if alterations in MHCII secondary structure accompany the different 
thermodynamic profile of the various complexes, we used far-UV circular dichroism (CD) 
spectroscopy to probe conformational specificities of HA, and HASG bound to DR1 or the 
b81mut (Figure A.2 A). The CD spectrum of empty DR1 and that of empty b81mut were 
substantially similar to each other but altered relative to that of the HA/DR1 and HA/b81mut 
complexes, exhibiting decreased intensity in the positive band at short wavelengths as well as in 
the negative band centered at 210-220 nm. These alterations are consistent with those observed 
in similar investigations performed by other groups on human and murine MHCII (8, 9, 25, 34,
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35). Also the spectra relative to HASG bound to either DR1 or b81mut appear similar with 
respect to each other, but different as compared to HA spectra, with values of ellipticity closer to 
the ones observed for the empty DR.
We then investigated possible differences in protein structure between the various 
complexes and empty MHCII by thermal denaturation measured as change in ellipticity at 204 
nm (Figure A.2 B and A.2 C). Empty DR1 and b81mut featured a thermal denaturation with a 
midpoint temperature of the thermal unfolding transition Tm of ~68 °C. The presence of the 
peptide increased the stability of the MHCII, though this effect appears to be a function of the 
bound peptide and the MHCII, in that complexes featuring smaller enthalpic contributions to 
binding energy undergo denaturation at lower temperature (Table A.2). The slope of the 9 versus 
temperature plot indicates a cooperative nature of denaturation. The low cooperativity of 
denaturation of empty MHCII suggested by the broad curve indicates that the number or strength 
of intramolecular contacts in this form is limited, resulting in a denaturation enthalpy AHm value 
as low as ~190 kJ mol'1. Cooperativity of denaturation for peptide-bound MHCII increased with 
respect to empty MHCII, as indicated by the steepness of the slope, and also in this case the 
effect appears to be a function of the peptide. To quantitate this effect we derived AHm, and the 
difference in heat capacity ACp between the folded and unfolded states. The values for AHm and 
ACp (Table A.2) indicate a global effect of peptide in stabilizing the overall folded MHC 
structure; however the lower enthalpy of denaturation for the multiple-substituted complexes 
would reflect a structurally “loose” conformation (35). These observations indicate that the 
thermodynamic profile of a pMHCII dyad is correlated with the conformation of the complex 
and its secondary structure.
MD simulation reveals greater flexibility in complexes whose formation is associated with 
smaller entropic penalty.
In order to assess whether differences in entropic contribution to binding energy and variation of 
secondary structures are correlated to differences in conformational flexibility, we performed 
large-scale molecular dynamics simulations of unbound MHCII molecules and MHCII bound to 
the peptides under scrutiny. The binding dynamics of DR1 and b81mut bound to the two 
peptides differed during the simulation time of 60 ns. We probed root mean square deviation 
(RMSD) and root mean square fluctuation (RMSF) variation between the different structures.
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RMSD for all the Ca atoms of the residues forming the binding site from the initial structure 
were calculated which was considered as the central criterion to measure the protein system. As 
shown in Figure A.3 A, unbound DR1 and b81mut showed deviations throughout the simulation 
from their respective starting structures, resulting in backbone RMSD ~3.2 A for DR1 and ~3.3 
A for b81mut during the simulation. Complexes showed a distinct trend of deviation when 
compared to the unbound MHCII, in keeping with simulations performed by other groups on the 
same system (36-38). Interestingly, the overall RMSD fluctuations were very much similar 
between the HA complex bound to either DR1 (~1.5 A) or b81mut (~1.6 A). However, DR1 
bound and b81mut bound to HASG showed more pronounced fluctuations together with a 
greater difference between the average RMSD values after the relaxation period (respectively 
~2.3 A, ~2.6 A). These results suggest a greater conformational lability of the overall binding 
site in the case of multiple substituted complexes with altered thermodynamic profiles as 
compared to the HA/DR1 complex.
With the aim of determining whether the nature of the bound peptide might affect protein 
dynamic behavior in specific regions of the complex, the RMSF values of MHCII backbone 
residues were calculated for the different complexes (Figure A.3 B). Analysis of fluctuation 
score revealed the presence of higher degree of flexibility in DR1 or b81mut bound to HASG as 
compared to complexes containing HA peptide. The presence of higher RMSF values in the 
former structure suggests that combining the P2V"S and the P10A"G substitutions in the peptide, 
or breaking the b81 H-bond in the HASG/DR1 complex reduced constraints in the structural 
flexibility of the bound protein. The largest difference in conformational mobility can be 
attributed to the a-helices and to the Ig-like domains of MHCII membrane-proximal region. In 
particular, comparison of the average structure of the wt complex with the substituted ones 
indicate that, when structural shifts are visible, these involve the a-chain residues 43-54 (Figure 
A.3 B, arrows) as well as the b-chain residues 63-68 and 79-90 in a peptide and MHCII- 
dependent fashion (Figure A.3 C arrows). Such variations in flexibility, especially of the a-chain 
residues 43-54, a stretch of amino acids with possible involvement in DM binding, has already 
been described (16, 17, 37, 38).
Based on the published structure, 14 H-bonds are established between MHCII helices and 
the peptide backbone. In particular, residues Phe a51, and Ser a53, establish main chain-main 
chain interactions, whereas side chains of Asn a62, Asn a69, Arg a76, Asp b57, Trp b61, Arg
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b71, His b81, Asn b82 form H-bonds with the peptide backbone. As shown in Figure A.3 D, the 
analysis of the overall complex H-bonding established by the aforementioned residues shows 
that the HA-containing complexes form more numerous and more stable H-bonds, whereas the 
number of H-bonds decreases in the case of complexes formed with HASG. Obviously, His b81 
contribution was computed only for complexes formed by DR1, substituted by Arg in the 
mutated complexes. These observations are further evidence of the increase MHCII structural 
flexibility in multiple substituted complexes.
The graphic rendering of the MD-based structure of HASG/DR1 in comparison with 
HA/DR1 is shown as an example of the peptide-dependent conformation assumed by a complex, 
in particular at the N-terminal region (Figure A.4 A and A.4 B). The most noticeable alterations 
with respect to the wt complex are relative to aW43, which rotates away from the binding site 
and increases solvent exposure and a shift of ~4A of aF51 towards the groove, resulting in a 
narrowing of the binding site at that end. Finally, aF54 rotates in the direction of the solvent in 
the substituted complex as a consequence of the inability to form an H-bond with the backbone 
of a more fluctuating, loosely tethered peptide. In Figure A.4 C and A.4 D the modifications in 
the average structures of the substituted complexes in comparison with the HA/DR1 are shown.
Taken together, these results indicate that the complexes of which formation is associated 
with the smallest entropic penalty, exhibit the most flexible behavior, particularly in the region 
that has been mapped as the DM/MHCII recognition site.
pMHCII affinity for DM  and susceptibility to DM-mediated peptide exchange are determined by 
the thermodynamic and structural correlates o f complexation.
We have shown that pMHCII dyads with comparable free energy decrease of complexation may 
rely on different enthalpic and entropic contributions, and a correlation can be observed between 
thermodynamic profile and structural features of the complex. We hypothesized that these 
differences in energetics and structure across complexes may impact DM-susceptibility, 
particularly as a consequence of the different availability of residues within the N-terminal 
region to interact with DM. To test this possibility, we measured the affinity of DM to the 
various complexes by a surface plasmon resonance (SPR) binding assay (Figure A.5). Specific 
saturable, dose-dependent binding was observed for HASG bound to either MHCII molecules, 
whereas no DM binding could be measured for the HA peptide bound to either DR1 or b81mut.
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Equilibrium binding analysis revealed KD values ~1.5 mM. To ensure that the binding was 
specific we performed these experiments at pH 7.4 and pH 5.4. The significant reduction in 
binding at pH 7.4 is consistent with the known pH effect on DM activity (Supplemental Figure 
A.1); moreover, no binding could be observed for empty DR1 and b81mut. These results clearly 
indicate that the complexes of which formation is correlated to a smaller entropic penalty and 
potentially featuring an increased structural flexibility, are preferential ligands for DM.
Finally, to investigate whether the differences in DM-affinity correlate with differences in 
DM activity, we measured the release of FAM-labeled peptides in the presence and in the 
absence of 3 fold excess DM from DR1 (Figure A.6 A) and b81mut (Figure A.6 B) via 
fluorescence polarization. DM-susceptibility was calculated as kof -fold increase = 
koff[DM+]/koff[DM-]. We correlated DM-susceptibility with the restraint of conformational flexibility 
associated with complex formation (TDS/DG). As shown in Figure A.6 C, an exponential 
relationship between residual entropy and DM-susceptibility can be determined: complexes with 
limited conformational flexibility (right side of the plot) are the most stable in the presence of 
DM, whereas complexes with greater residual entropy are more susceptible to DM activity.
Taken together, these results indicate that the thermodynamic signature of a given pMHCII 
complex is correlated to the probability for that complex to assume a conformation targetable by 
DM and, as a consequence, it also determines complex susceptibility to DM activity.
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Discussion
Recent structural studies have provided important insights into how DM interacts with MHCII to 
mediate peptide exchange (14, 16, 17). From these structures and the most recent 
biophysical/biochemical analyses it would appear that DM-susceptibility of a pMHCII complex 
is a function of the frequency with which the P1 pocket is emptied or the probability for the 
complex to assume a conformation in which critical residues are available for interaction with 
DM. However, it is still unclear which of these properties is a determinant of DM-susceptibility, 
and whether they are related to the sequence of the bound peptide. Conformational analysis for 
just a few pMHCII complexes have been carried out, limiting our capacity to infer general rules 
of DM-susceptibility on the basis of the nature of the peptide and structural determinants. 
Moreover, we still do not have a conclusive understanding of DM action on the complex and 
how it skews the binding of peptides.
In this work we show that the thermodynamic mechanisms adopted by peptides and 
MHCII molecules to interact may be different, as defined through the enthalpic and entropic 
components of binding free energy decrease, even in the case of peptides with comparable 
affinity for the same MHCII. Whereas these energy variations maintain an enthalpy-based 
mechanism of complex formation, CD and MD simulation indicate that they are sufficient to 
affect the conformation and the lability of the resulting complex. SPR and FP-based analyses 
reveal that these conformational differences are correlated with the affinity of the complex for 
DM and its susceptibility to DM-mediated peptide exchange.
Peptide binding in the absence of DM is a flexible process, and does not rely on 
independent contributions from pocket/anchor interactions and H-bonds, but is a function of the 
synergism involving multiple single-point interactions (30, 31, 39). MHCII molecules feature 
conformational lability, and the a-subunit 310 helical region with the adjacent extended strand, 
the P2 Ig-like domain, and the pronounced kink in the P-subunit helical region P62-71 are the 
most subject to conformational heterogeneity, either in the empty or in the bound state (40). We 
have previously shown that the effect of MHCII flexibility on the transition from the empty to 
the bound state (and vice versa) is evidenced by phenomena such as cooperativity and isothermal 
entropy-enthalpy compensation, the latter also confirmed in the present work (30). These 
observations suggest a thermodynamic-structural model by which peptides and MHCII bind by 
optimizing the available interactions through search of conformational space and, as they bind,
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system flexibility is restrained; the relative enthalpic and entropic contributions to binding free 
energy decrease determines the structure and conformational lability of the resulting complex.
How does the overall binding property of the peptide determine DM-susceptibility of the 
complex? The correlation between thermodynamic mechanism of binding and complex structure 
strongly suggests that the interplay between entropy, enthalpy and binding cooperativity are 
responsible for determining the probability by which a complex is generated and assumes a more 
or less DM-susceptible conformation. Indeed, the CD and MD analyses show that a complex, of 
which formation is correlated to a smaller entropic penalty, features greater conformational 
mobility and a secondary structure closer to the empty MHCII form as compared to an 
isoenergetic complex of which formation involves a larger enthalpic contribution. As a 
consequence, regions within the N-terminal side of the former complexes are expected to 
disengage from interactions with the peptide and be more amenable to interaction with DM at a 
higher frequency than the latter.
Studies performed with peptides unable to fill the P1 pocket have suggested a model by 
which DM-susceptibility is a function of the interactions at the P1 region (9, 13, 15, 41, 42). This 
model has been further refined by a recent structure of DM-DR1 complex with DR1 covalently 
linked to a peptide lacking three N-terminal residues (14). According to this latter study, 
suboptimal P1 anchor residues would favor formation of a complex in which the peptide N- 
terminal dissociates from MHCII, and residues aW43, aF51 and PF89 would rotate out of the 
pocket, consequently becoming available for DM binding and not accessible to interactions with 
the peptide. The destabilized complex bound to DM would be able to exchange peptides and DM 
would dissociate from DR1 once the latter is bound to a peptide able to fill the P1 pocket and 
possibly capable of forming interactions at the other three major pockets. However, this model 
does not fully account for the observations that even peptides with optimal “anchor” residues are 
DM-susceptible when bound to MHCII (43, 44). In a similar fashion, this same model is not able 
to explain the evidence that such peptides are unsuccessful in replacing completely a DM- 
sensitive ligand such as CLIP during a DM-mediated peptide exchange reaction (33). The 
alternative classical hypothesis of DM-susceptibility based on disruption of one or multiple H- 
bonds, especially the one established between the His at b81 of the MHCII and the peptide 
backbone (45, 46) has been challenged by several studies in which complexes lacking one or 
more of these same H-bonds appeared to be more susceptible to DM than their wild-type
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counterparts (47-49). We have previously shown that the disruption of the b81 H-bond affects 
peptide binding and complex kinetic stability differently on the basis of overall energetics of the 
complex (30, 32). Our current analysis indicates that also the effect of the b81 H-bond on DM- 
susceptibility varies across complexes, of which conformation and lability differ, as determined 
by the thermodynamic mechanism of binding.
The model we suggest can explain and reconcile all these conflicting observations: 
structural studies have mapped the DM/MHCII recognition site to the extended strand loop of the 
alpha chain (14, 16, 50, 51), which is also one of the most dynamic regions of the complex (40). 
The occupancy state of the P1 pocket region ought to be one important determinant of the 
geometry of the DM/DR interface. However, due to cooperative effects, stable encapsulation of 
peptide side chains in the P1 pocket and concurrent formation of the H-bond network at the N- 
terminal side of the complex relies on interactions formed at other positions of the groove, 
including the C-terminal side. Indeed, a peptide featuring a suboptimal or poor P1 anchor, such 
as A for HA/DR1, not stabilized by other interactions across the groove, will be sufficient to 
promote those structural rearrangements leading to a DM-susceptible form of the complex. 
However, it would be theoretically possible to rescue suboptimal P1 anchors from causing DM- 
susceptibility by modifying interactions at other positions of the peptide. For instance, we are 
currently examining the combined effect of the P1N substitution, which is significantly 
destabilizing in the context of HA peptides, with P4E and P7G, which appear to increase stability 
of the peptide in a DM-mediated exchange reaction. In the same vein, the role of the b81 H-bond 
and of any other H-bond in favoring the conformational rearrangement required for DM- 
susceptibility are a function of the overall binding energy and conformational flexibility of the 
system. Indeed, DM-susceptibility of HASG is increased by the b81 mutation, whereas HA is 
barely affected. We can also propose an explanation as to why the complex formed by a P1A- 
substituted HA peptide with the b81mut does not behave differently in terms of DM- 
susceptibility as compared to a complex involving the wtMHCII: since the emptied P1 pocket, 
not sufficiently stabilized by other interactions across the binding groove, is already rearranged 
in the DM-susceptible form, the contribution to this rearrangement of the b81 H-bond loss is 
expected to be minimal (45). In addition to the effect of multiple interactions across the groove 
on the binding state of the peptide at the P1 pocket region, there is also a direct effect of each 
position on the conformation of the complex. Finally, the thermodynamic mechanism adopted by
55
the system will determine the residual flexibility post-complexation, hence the probability for the 
DM/DR interaction site to assume a conformation amenable to DM binding. Thus, we can define 
a spectrum of DM-susceptibility in which one extreme is represented by complexes with reduced 
conformational mobility, fully occupied P1 pocket region (such is the case of HA306-319 bound to 
DR1), or suboptimally occupied but stabilized, that do not bind DM and are not amenable to 
DM-mediated exchange. The opposite extreme would be represented by complexes of which 
structure and lability would permit DM interaction, but of which limited intrinsic stability cannot 
be further reduced by DM action, such as “anchorless” HA306-319. Between these two extremes 
are included all those pMHCII systems that can form a complex, of which overall structure and 
flexibility determined by respective binding thermodynamics define DM-affinity and 
susceptibility.
Two aspects of the present study pose a limit to the generalization of our conclusions. 
First, this analysis is limited to four, closely related DR/HA variant complexes, and it might be 
argued that the identified thermodynamic correlates of DM susceptibility are valid only in such 
instances where limited structural changes are applied to the system. This consideration should 
necessarily be taken into account if we attempted to derive rules of DM-susceptibility on a 
peptide-sequence basis. Extending this study to a larger number of complexes formed by 
different MHC alleles and different peptides will help reach that goal. Nevertheless, this 
argument does not invalidate the correlation between thermodynamic mechanism of binding and 
DM-susceptibility, irrespective of the structural features of the peptide, since the analyzed 
thermal parameters are state functions. Moreover, this argument would not nullify our 
observation that peptides able to fill the P1 pocket can be DM-susceptible, which is a clear 
evidence against a P1-centric model of DM function.
The second limitation is that the DM dissociation experiments are correlative, and although 
supportive, the molecular dynamic simulation studies are not conclusive as to the structure of the 
conformers and the molecular aspects of the complex associated to DM activity. EPR and NMR- 
based experiments are underway to determine the structure of the conformers and mechanisms of 
DM interaction. Interestingly, our findings are consistent with a recent structural (and kinetic) 
study showing that DM-susceptibility would be determined by a dynamic MHCII conformation, 
and indicating the modifications the complex undergoes as it switches from a DM-resistant to a
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DM-susceptible form (52). We expect to identify similar conformational rearrangements in our 
system by structural analysis.
The initial observations relative to DM activity indicating a role in facilitating CLIP 
release from MHCII have determined the adoption of kinetics-based approaches to the study of 
DM-susceptibility (3, 21, 53-55). However, the conclusions reached from these experiments 
have been controversial, and they are not easily applicable to the problem of epitope selection in 
the context of the APC. The panoply of peptides generated by endocytosed proteins includes a 
consistent number of ligands with low affinity for a given MHC allele, sequences with 
intermediate affinity and few high-affinity ones. At the end of epitope selection in DM- 
competent cells, MHCII molecules reach a thermodynamic equilibrium in which they are 
complexed with stable, high affinity binders. It is difficult to explain how the MHC-peptide 
system may reach such equilibrium intrinsically in consideration of the evidence that the transit 
time of an MHCII through the MIIC is comparable to the dissociation rate of many low- 
intermediate affinity peptides (56). Indeed, if this were the case, the expectation would be that 
the majority of MHC molecules are bound to low- or intermediate-affinity peptides that are in 
excess, as a consequence of a kinetic control of the selection process. We prefer the possibility 
that epitope selection is regulated by a mechanism able to enhance the thermodynamic control of 
the peptide binding process, with DM the likeliest factor determining the thermodynamic 
equilibrium of the endosomal machinery. This possibility is supported by the evidence that DM 
deficient APCs present a significant amount of empty MHCII or MHCII bound to low-affinity 
peptides (55, 57). Our observations are a further confirmation of the correlation between 
thermodynamic signature of a pMHCII complex, its conformational flexibility, and susceptibility 
to DM-mediated peptide exchange. Thus, in conjunction with the published structural studies, 
our work provides a comprehensive theory to explain peptide binding and DM activity within the 
timeframe allotted for epitope selection.
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Figure A.1 -  Representative Raw ITC Data Titrating HA-derived Peptides into HLA-DR1 
and P81mut and the Fitted Binding Curves. Starting protein concentrations in the calorimeter 
cell was ~5 pM, whereas concentrations in the syringe was ~50 pM. ITC injection volumes were 
2 pl, and injections were performed over 10 s spaced 180 s apart to allow for a complete return to 
baseline. Data were processed and integrated with Origin software. Single data sets were fit to a 
single site ITC binding model, using a baseline offset parameter to account for heat of dilution. 
The first data point was excluded from analysis due to dilution across the injection needle tip. 
Experiments were performed at least in triplicate. Measured thermal parameters are indicated in 
Table A.1.
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Figure A.2 -  Far-UV CD and Thermal 
Stability Analysis of Empty MHCII 
Molecules and Different pMHCII 
Complexes. (A) Changes in secondary 
structure of empty MHCII molecules and 
molecules bound to either HA or HASG.
(B, C) Thermal denaturation curves of 
empty MHCII (black line) and MHCII 
bound to HA (red line), HASG (blue line) 
are shown for reactions involving DR1 (B) 
and P81mut (C). Spectra were acquired on 
a Jasco J-720. Complexes were exchanged 
into 5 mM sodium phosphate/5 mM sodium 
acetate buffer, pH-adjusted with 
concentrated stocks of HCl and filtered to a 
final concentration of 3.5 pM (~0.2 mg/ml). 
For the thermal stability analysis, 
temperature was increased by 1.0 K min-1. 
The extent of thermal denaturation was 
measured as a change in ellipticity at 204 
nm. Thermodynamic parameters derived as 
described in Methods are reported in Table
A.2.
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Figure A.3 - MD Simulation of Empty MHCII and MHCII Bound to Different Peptides.
The starting conformation was extracted from PDB 1DLH. The complexes formed by HA- 
substituted peptides or by P81mut were prepared by applying the appropriate mutations within 
the sequence of the wt peptide or DR1 with the VMD mutator plugin. (A) RMS deviation over 
time for the peptide-loaded (red: HA, blue: HASG) and free (black) simulations, for the DR1 
(top) and P81mut (bottom) a1p1 binding site. (B, C) RMS fluctuation during the first 10 ns of 
simulation for each residue (all atoms included) for the a-subunit (B) or b-subunit (C) of the 
DR1 (top) or p81mut (bottom) complexes. Color code as in panel A. (D) H-bonding between 
MHCII helices and peptide backbone for the four complexes is shown during the first ten ns of 
simulation.
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Figure A.4 -  Structural Model of Peptide-dependent pMHCII Complex Modifications. In
the top panels, the most favored conformers of the HASG/DR1 and HA/DR1 complexes are 
shown superimposed at the N-terminal region from the side (A) and from the top (B). Residues 
postulated to be involved in DM interaction are shown as sticks, and predicted conformational 
rearrangements are indicated. In the bottom panels, the most favored conformers of the 
HASG/DR1 (C), and HASG/b81mut (D) complexes are shown superimposed with HA/DR1 
complex. Regions undergoing the most pronounced conformational rearrangements are 
indicated. In all panels the wt complex is rendered in light pink (a-chain) and magenta (b-chain). 
The substitute complex is shown in green and cyan. The peptide is not shown in these renderings 
for graphic clarity.
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Figure A.5 - SPR Assay of DM Interaction with pMHCII Complexes. Affinity measurements 
were performed by injecting the various pMHCII complexes or empty MHCII molecules in two 
fold dilutions and at seven concentrations from 8 mM and flowing them over DM-coated CM5 
sensor chip at flow rate of 5pl/min for 5 min and dissociated for 5 min. Binding to DM was 
analyzed for (A) unbound DR1, (B) unbound b81mut, (C) HA/DR1, (D) HA/b81mut, (E) 
HASG/DR1, (F) HASG/b81mut. These experiments were repeated at least three times. Binding 
data were fit to a heterologous binding model using BIAeval software to derive the indicated KD 
values.
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Figure A.6 -  FP-based Analysis of DM- 
susceptibility. Dissociation rates of DR1- 
(A) and P81mut-peptide complexes (B) in 
the absence and in the presence of DM. 
Data are expressed as the fraction of 
complex remaining relative to t = 0. 
Reactions were performed in triplicate, and 
data series represent one of three 
independent experiments. The lines 
represent the fit of the data to either a one- 
or a two-phase exponential function. (C) 
DM-susceptibility of the tested pMHCII 
complexes, calculated as peptide koff -fold 
increase, inversely correlates with the 
restraining of conformational flexibility 
associated with binding, measured as 
entropic contribution to free energy 
decrease. The line represents the fit of the 
data to a single exponential function.
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Supplementary Figure A.1 -  SPR Assay of DM Interaction with pMHCII Complexes at pH
7. Affinity measurements were performed by injecting the various pMHCII complexes in two 
fold dilutions and at seven concentrations from 8 mM and flowing them over DM-coated CM5 
sensor chip at flow rate of 5pl/min for 5 min and dissociated for 5 min. Binding to DM was 
analyzed for (A) HA/DR1, (B) HA/b81mut, (C) HASG/DR1, (D) HASG/b81mut. These 
experiments were repeated three times.
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Table A.1: Binding Affinity and Thermodynamic Parameters for each pHLAII dyad tested. 
Mutations applied to the HA peptide are in bold.
Complex Sequence n K d (nM) DG (kJ mol-1) DH  (kJ mol-1) TDS (kJ mol-1)
HA/DR1 PKYVKQNTLKLAT 0.93 15.6 ± 1.3 -44.5 ± 1.6 -53.6 ± 0.7 -9.02 ± 0.08
HA/b81mut 0.96 11.2 ± 1.5 -45.4 ± 1.4 -46.9 ± 0.5 -1.50 ± 0.06
HASG/DR1 PKYSKQNTLKL GT 0.98 82.1 ± 6.3 -40.4 ± 1.4 -40.1 ± 0.4 0.34 ± 0.01
HASG/b81mut 0.94 132.5 ± 9.4 -39.2 ± 1.3 -30.5 ± 0.4 8.78 ± 0.11
Table A.2 -  Midpoint Temperature, Enthalpy and Heat Capacity of the unfolding transition 
during thermal denaturation of empty HLAII and HLAII bound to either HA or HASG
Complex Tm K (°C) DHm (kJ mol-1) DCp (kJ mol-1 K-1)
Empty DR1 341 (68) 192 ± 8 0.9 ± 0.4
Empty b81mut 341 (68) 188 ± 6 0.9 ± 0.4
HA/DR1 352 (79) 298 ± 15 6.5 ± 1.1
HA/b81mut 349 (76) 310 ± 17 6.1 ± 0.9
HASG/DR1 345 (72) 229 ± 12 4.9 ± 0.6
HASG/b81mut 343 (70) 212 ± 15 5.2 ± 0.7
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